atrs-10q_20170930.htm

Large accelerated filer

Accelerated filer

Non–accelerated filer

☐ (do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001564590-17-022312.txt : 20171107 0001564590-17-022312.hdr.sgml : 20171107 20171107165252 ACCESSION NUMBER: 0001564590-17-022312 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1208 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 171184088 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 10-Q 1 atrs-10q_20170930.htm 10-Q atrs-10q_20170930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2017

Commission File Number 1-32302

ANTARES PHARMA, INC.

A Delaware Corporation

IRS Employer Identification No. 41-1350192

100 Princeton South, Suite 300

Ewing, New Jersey 08628

(609) 359-3020

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s Common Stock, $.01 par value, as of November 1, 2017 was 156,674,504.

ANTARES PHARMA, INC.

INDEX

			PAGE

PART I.		FINANCIAL INFORMATION	3

	Item 1.	Financial Statements	3

		Consolidated Balance Sheets, as of September 30, 2017 (Unaudited) and December 31, 2016	3

		Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2017 and 2016	4

		Consolidated Statements of Comprehensive Loss (Unaudited) for the three and nine months ended September 30, 2017 and 2016	5

		Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2017 and 2016	6

		Notes to Consolidated Financial Statements (Unaudited)	7

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26

	Item 4.	Controls and Procedures	26

PART II.		OTHER INFORMATION	27

	Item 1.	Legal Proceedings	27

	Item 1A.	Risk Factors	27

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31

	Item 3.	Default Upon Senior Securities	31

	Item 4.	Mine Safety Disclosures	31

	Item 5.	Other Information	31

	Item 6.	Exhibits	31

		SIGNATURES	32

PART I – FINANCIAL INFORMATION

Item 1.

FINANCIAL STATEMENTS

ANTARES PHARMA, INC.

CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2017			2016
	(Unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	27,433,489		$	27,714,588
Short-term investments		9,976,984			—
Accounts receivable		10,146,966			9,073,173
Inventories		7,942,376			5,326,962
Deferred costs		1,213,507			1,773,446
Prepaid expenses and other current assets		1,680,208			1,376,299
Total current assets		58,393,530			45,264,468
Equipment, molds, furniture and fixtures, net		17,296,719			17,867,412
Patent rights, net		1,630,785			2,044,608
Goodwill		1,095,355			1,095,355
Other assets		53,778			53,607
Total Assets	$	78,470,167		$	66,325,450
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable	$	8,245,154		$	7,884,983
Accrued expenses and other liabilities		6,394,379			5,872,846
Deferred revenue		2,842,801			6,149,087
Total current liabilities		17,482,334			19,906,916
Long-term debt		24,791,214			—
Deferred revenue – long term		200,000			1,200,000
Total liabilities		42,473,548			21,106,916
Stockholders’ Equity:
Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding		—			—
Common Stock: $0.01 par; 300,000,000 shares authorized; 156,425,904 and 155,167,677 issued and outstanding at September 30, 2017 and December 31, 2016, respectively		1,564,259			1,551,677
Additional paid-in capital		301,703,929			297,826,433
Accumulated deficit		(266,570,874	)		(253,445,306	)
Accumulated other comprehensive loss		(700,695	)		(714,270	)
		35,996,619			45,218,534
Total Liabilities and Stockholders’ Equity	$	78,470,167		$	66,325,450

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
Revenue:
Product sales	$	13,327,525		$	11,049,840		$	30,708,750		$	30,580,889
Development revenue		1,485,091			2,101,203			7,894,640			6,466,974
Licensing revenue		19,486			38,618			1,057,204			128,040
Royalties		220,295			289,102			815,421			850,022
Total revenue		15,052,397			13,478,763			40,476,015			38,025,925
Cost of revenue:
Cost of product sales		7,600,180			7,206,280			16,681,689			18,670,363
Cost of development revenue		922,717			827,441			3,677,363			3,457,197
Total cost of revenue		8,522,897			8,033,721			20,359,052			22,127,560
Gross profit		6,529,500			5,445,042			20,116,963			15,898,365
Operating expenses:
Research and development		3,289,445			5,958,550			9,535,089			15,554,599
Selling, general and administrative		8,185,865			5,622,937			23,013,130			20,240,635
Total operating expenses		11,475,310			11,581,487			32,548,219			35,795,234
Operating loss		(4,945,810	)		(6,136,445	)		(12,431,256	)		(19,896,869	)
Interest expense		(625,938	)		—			(794,129	)		—
Other income		119,227			15,462			197,003			58,313
Net loss	$	(5,452,521	)	$	(6,120,983	)	$	(13,028,382	)	$	(19,838,556	)
Basic and diluted net loss per common share	$	(0.03	)	$	(0.04	)	$	(0.08	)	$	(0.13	)
Basic and diluted weighted average common shares outstanding		156,400,702			155,060,811			155,851,639			154,952,060

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
Net loss	$	(5,452,521	)	$	(6,120,983	)	$	(13,028,382	)	$	(19,838,556	)
Foreign currency translation adjustment		(3,621	)		2,632			13,575			(7,820	)
Comprehensive loss	$	(5,456,142	)	$	(6,118,351	)	$	(13,014,807	)	$	(19,846,376	)

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	September 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(13,028,382	)	$	(19,838,556	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		2,371,453			1,886,823
Depreciation and amortization		1,520,197			1,371,538
Loss on disposal of equipment		22,600			17,785
Write-off of capitalized patent costs		45,600			—
Accretion of interest expense		66,406			—
Amortization of debt issuance costs		18,347			—
Amortization of premiums and discounts on investment securities		(16,638	)		10,913
Changes in operating assets and liabilities:
Accounts receivable		(1,069,614	)		(624,232	)
Inventories		(2,615,414	)		(999,158	)
Prepaid expenses and other assets		(299,825	)		2,922,527
Deferred costs		559,939			(762,413	)
Accounts payable		701,704			3,308,607
Accrued expenses and other current liabilities		549,929			(146,376	)
Deferred revenue		(4,308,571	)		1,156,309
Net cash used in operating activities		(15,482,269	)		(11,696,233	)
Cash flows from investing activities:
Purchase of investment securities		(9,963,978	)		—
Purchases of equipment, molds, furniture and fixtures		(878,855	)		(4,278,643	)
Additions to patent rights		(83,592	)		(103,788	)
Proceeds from maturities of investment securities		—			12,000,000
Net cash (used in) provided by investing activities		(10,926,425	)		7,617,569
Cash flows from financing activities:
Proceeds from issuance of long-term debt		25,000,000			—
Payment of debt issuance costs		(293,538	)		—
Proceeds from exercise of stock options		1,670,149			24,071
Taxes paid related to net share settlement of equity awards		(248,709	)		(64,096	)
Net cash provided by (used in) financing activities		26,127,902			(40,025	)
Effect of exchange rate changes on cash		(307	)		1,440
Net decrease in cash and cash equivalents		(281,099	)		(4,117,249	)
Cash and cash equivalents:
Beginning of period		27,714,588			32,898,676
End of period	$	27,433,489		$	28,781,427
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$	92,674		$	552,556
Additions to patent rights recorded in accounts payable and accrued expenses	$	6,160		$	23,369

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.	Description of Business

Antares Pharma, Inc. (“Antares” or the “Company”) is an emerging, specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures, for itself or with partners, novel therapeutic products using its advanced drug delivery technology to enhance the existing drug compounds and delivery methods. The subcutaneous injection technology platforms include the VIBEX^® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. The Company has a portfolio of proprietary and partnered products, including approved commercial products and several partnered product candidates in advanced stages of development and under active review by the U.S. Food and Drug Administration (“FDA”). The Company has formed significant strategic alliances with Teva Pharmaceutical Industries, Ltd. (“Teva”), AMAG Pharmaceuticals, Inc. (“AMAG”), Ferring Pharmaceuticals Inc. and Ferring B.V. (together “Ferring”), and has multiple ongoing internal and partnered product development programs.

The Company markets and sells its proprietary product OTREXUP^® (methotrexate) injection in the U.S., which was launched in February 2014. OTREXUP^®is the first subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector approved by the FDA. OTREXUP^® is indicated for adults with severe active rheumatoid arthritis (“RA”), children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis.

The Company, with its commercialization partner Teva, launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. In December 2015, the Company received FDA approval for an Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex^® STATdose Pen^®. Sumatriptan Injection USP represents the Company’s first ANDA approval of a complex generic and second product approved using the VIBEX^® auto injector platform.

The Company is developing XYOSTED^TM (testosterone enanthate) injection for testosterone replacement therapy, and submitted a 505 (b) (2) New Drug Application (“NDA”) to the FDA in December 2016. On October 20, 2017, the Company received a Complete Response Letter (the “CRL”) from the FDA for XYOSTED^TM, which identified two deficiencies and indicated that the NDA cannot be approved in its present form. The Company is assessing the content of the CRL, including the information that may be needed to address the deficiencies.

2.	Basis of Presentation and Significant Accounting Policies

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission's Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

Investments

The primary objectives of the Company’s investment policy are to protect principal, maintain adequate liquidity and maximize returns. The Company’s investments consist of U.S. Treasury bills and government agency notes that are classified as held-to-maturity because the Company has the intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The securities are carried at their amortized cost and the fair value is determined by quoted market prices. At September 30, 2017, the Company’s investments had a carrying value of $9,976,984, which approximated fair value. The Company held no investments as of December 31, 2016.

Inventories

warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,000,000 and $900,000 at September 30, 2017 and December 31, 2016, respectively. Inventories consist of the following:

	September 30,		December 31,
	2017		2016
Inventories:
Raw material	$	126,070	$	142,491
Work in process		4,357,554		2,429,075
Finished goods		3,458,752		2,755,396
	$	7,942,376	$	5,326,962

Revenue Recognition — OTREXUP^®

The Company began detailing OTREXUP^® to health care professionals in February 2014. OTREXUP^® is sold in packages of four pre-filled, single-dose disposable auto injectors to wholesale pharmaceutical distributors, its customers, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration.

Prior to the first quarter of 2017, the Company could not reliably estimate expected returns of OTREXUP^® at the time of shipment given its limited sales history of the product. Accordingly, the recognition of revenue was deferred on product shipments until the rights of return no longer existed, which occurred at the earlier of the time OTREXUP^® units were dispensed through patient prescriptions or expiration of the right of return of the product. Patient prescriptions dispensed were estimated using third-party market prescription data.

In the first quarter of 2017, the Company determined it had developed sufficient historical information to reasonably estimate future returns of OTREXUP^®and began recognizing revenue, net of estimated returns, upon delivery to the distributors. As a result, the Company recognized an additional $1,297,054 for product shipped to distributors in previous periods that was not previously recognized as revenue at the time of shipment, net of the returns allowance established in the first quarter of 2017. The Company also recognized $254,425 of related product costs that had been previously deferred. The net impact of these changes resulted in a decrease in net loss of $1,042,629, less than $0.01 per share, for the nine months ended September 30, 2017.

Product sales revenue for OTREXUP^®is presented net of estimated returns and product sales allowances for wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs. The estimated product returns reserve was $650,000 as of September 30, 2017 and zero at December 31, 2016. Product sales allowances were $1,986,553 as of September 30, 2017 and $1,540,488 as of December 31, 2016.

Product Sales Allowances

The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, it may be necessary to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Product sales allowances include:

Wholesaler Distribution Fees. Distribution fees are paid to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized.

Prompt Pay Discounts. The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

acquisition cost and the price the entity paid for the product. The Company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized.

Rebates. The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized.

Patient Discount Programs. The Company offers discount card programs to patients for OTREXUP^® in which patients receive discounts on their prescriptions that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on historical redemption experience and on estimated levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

Revenue Recognition — Sumatriptan Injection

Under a license, supply and distribution agreement with Teva for an auto-injector product containing sumatriptan, the Company produces devices and assembles product for shipment to Teva, and Teva is responsible for commercial distribution and sale of the product. The Company is compensated, and recognizes revenue, at cost for shipments of product delivered to Teva. The Company is also entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the quarter in which the commercial sales are made by Teva.

Sumatriptan Injection USP was launched for commercial sale in June 2016. Initially, given the limited access to sales data and the 45-day lag in reporting of the profit split from Teva, management was not able to estimate the profit margin the Company expected to receive from commercial sales made by Teva at the time of sale. Accordingly, prior to the third quarter of 2017, revenue from the profit sharing arrangement was recognized in the period following the commercial sales by Teva when amounts were reported and paid to the Company. Beginning in the third quarter of 2017, management determined it had developed sufficient history and is now able to obtain additional sales information in order to reasonably estimate and recognize revenue from the profit sharing arrangement when product is sold by Teva.

3.	Long-Term Debt

On June 6, 2017, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., for a term loan of up to $35,000,000 (the “Term Loan”), the proceeds of which are to be used for working capital and general corporate purposes. The first advance of $25,000,000 was funded upon execution of the Loan Agreement on June 6, 2017. Under the terms of the Loan Agreement, the Company may, but is not obligated to, request one or more additional advances of at least $5,000,000 not to exceed $10,000,000 in the aggregate, subject to the Company achieving certain corporate milestones and satisfying customary conditions. The Company must exercise its option to request additional advances prior to September 30, 2018.

The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022. The Term Loan accrues interest at a calculated prime-based variable rate with a maximum interest rate of 9.50%. As of September 30, 2017, the interest rate was 8.75%. Payments under the Loan Agreement are interest only until the first principal payment is due on August 1, 2019, provided that the interest only period may be extended to February 1, 2020 if the Company achieves certain corporate milestones. The Loan Agreement also requires the Company to pay a fee equal to 4.25% of the total original principal amount of all term loan advances (“End of Term Charge”), which is due upon repayment of the Term Loan at either maturity or earlier repayment, and imposes a prepayment fee of 1.0% to 3.0% if any or all of the balance is prepaid prior to the maturity date.

As of September 30, 2017, the carrying value of the Term Loan was $24,791,214, which consisted of the $25,000,000 principal balance outstanding and the End of Term Charge accrual of $66,406, less unamortized debt issuance costs of $275,192. The Company incurred debt issuance costs that, along with the End of Term Charge, are being amortized/accrued to interest expense over the term of the Term Loan using the effective interest method.

Future principal payments under the term loan, including the End of Term Charge, are as follows:

	September 30,
	2017
2017	$	—
2018		—
2019		3,075,781
2020		7,870,277
2021		8,602,959
Thereafter		6,513,483
	$	26,062,500

The Company believes that the carrying value of the Term Loan approximates its fair value based on the borrowing rates currently available for loans with similar terms.

4.	Stockholders’ Equity

On August 11, 2017, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company may offer and sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $30,000,000 through Cowen as the Company’s sales agent and/or as principal. Cowen may sell the common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended. The Company will pay Cowen a commission of 3.0% of the gross sales proceeds of any common stock sold through Cowen under the Sales Agreement. The Company is not obligated to make any sales of common stock under the Sales Agreement and no sales of common stock were made pursuant to the Sales Agreement in the period ended September 30, 2017.

5.	Share-Based Compensation

The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares authorized for issuance under the amended and restated Plan is 32,200,000 and the maximum number of shares of stock that may be granted to any one employee for qualified performance-based compensation during a calendar year is 4,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is ten years and the options typically vest in quarterly installments over a three-year period with a minimum vesting period of one year. As of September 30, 2017, the Plan had approximately 6,400,000 shares available for grant. Stock option exercises are satisfied through the issuance of new shares.

Stock Options

The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2017:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Shares			Price		Term (Years)		Value
Outstanding at December 31, 2016		11,313,909		$	1.84
Granted		2,975,667			2.67
Exercised		(1,062,693	)		1.57
Cancelled/Forfeited		(833,033	)		2.68
Outstanding at September 30, 2017		12,393,850			2.01		7.3	$	15,631,780
Exercisable at September 30, 2017		8,043,282		$	1.93		6.2	$	10,880,581

The per share weighted average fair values of all options granted during the nine months ended September 30, 2017 and 2016 were estimated as $1.62 and $0.54, respectively, on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior.

	September 30,
	2017		2016
Risk-free interest rate		1.8%		1.3%
Annualized volatility		53.4%		51.6%
Weighted average expected life, in years		6.0		6.0
Expected dividend yield		0.0%		0.0%

During the nine months ended September 30, 2017, stock option exercises resulted in cash proceeds to the Company of $1,670,149 and the issuance of 1,062,693 shares of common stock. Stock option exercises resulted in proceeds of $24,071 and the issuance of 21,492 shares of common stock in the nine months ended September 30, 2016.

The Company recognized $1,680,437 and $1,572,710 of compensation expense related to stock options for the nine months ended September 30, 2017 and 2016, respectively, and $692,834 and $505,663 for the three months ended September 30, 2017 and 2016, respectively. As of September 30, 2017, there was approximately $4,500,000 of total unrecognized compensation cost related to non-vested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.1 years.

Long Term Incentive Program

The Company’s Board of Directors has approved a long term incentive program (“LTIP”) for the benefit of the Company’s senior executives. Pursuant to the LTIP, the Company’s senior executives have been awarded stock options, restricted stock units (“RSU”) and performance stock units (“PSU”) with targeted values based on values granted to similarly situated senior executives in the Company’s peer group.

The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The RSUs vest in three equal annual installments. The PSU awards made to the senior executives vest and convert into shares of the Company’s common stock based on the Company’s attainment of certain performance goals as established by the Company’s Board of Directors over a performance period, which is typically three to five years.

The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table:

	Performance Stock Units					Restricted Stock Units
	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2016		1,347,289		$	1.50		822,658		$	1.39
Granted		689,180			3.12		689,180			2.69
Vested/settled		—					(287,508	)		1.49
Forfeited/expired		(502,308	)		2.16		(67,464	)		1.70
Outstanding at September 30, 2017		1,534,161		$	2.20		1,156,866		$	2.12

In 2017, 2016 and 2015, the LTIP awards include PSUs that may be earned based on the Company’s total shareholder return (“TSR”) relative to the Nasdaq Biotechnology Index (“NBI”) at the end of the performance period. The performance period is January 1, 2015 to December 31, 2017 for the 2015 award, January 1, 2016 to December 31, 2018 for the 2016 award and January 1, 2017 to December 31, 2019 for the 2017 award. Depending on the outcome of the performance goal, a recipient may ultimately earn a number of shares greater or less than their target number of shares granted, ranging from 0% to 150% of the PSUs granted. The fair values of the TSR PSUs granted was determined using a Monte Carlo simulation and utilized the following inputs and assumptions:

	2017 Award			2016 Award			2015 Award
Closing stock price on grant date	$	2.66		$	1.12		$	2.18
Performance period starting price	$	2.17		$	1.29		$	2.52
Term of award (in years)		2.57			2.58			2.59
Volatility		54.6	%		70.1	%		60.5	%
Risk-free interest rate		1.39	%		0.97	%		0.83	%
Expected dividend yield		0.00	%		0.00	%		0.00	%
Fair value per TSR PSU	$	3.10		$	1.25		$	1.71

The performance period starting price is measured as the average closing price over the last 20 trading days prior to the performance period start. The Monte Carlo simulation model also assumed correlations of returns of the prices of the Company’s common stock and the common stocks of the NBI companies and stock price volatilities of the NBI companies. The fair value of the target number of shares that can be earned under the TSR PSUs is being recognized as compensation expense over the performance period.

In connection with PSU awards, the Company recognized compensation expense of $239,995 and $11,331 for the nine months ended September 30, 2017 and 2016, respectively. Compensation expense recognized in connection with RSU awards was $451,021 and $302,782 for the nine months ended September 30, 2017 and 2016, respectively.

Shares issued in connection with LTIP awards that vested in the nine months ended September 30, 2017 and 2016 were net-share settled such that the Company withheld shares with a value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld to satisfy tax obligations were 97,586 and 65,575 in the nine months ended September 30, 2017 and 2016, respectively, and were based on the fair value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $248,709 and $64,096 in the nine months ended September 30, 2017 and 2016, respectively, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.

6.	Significant Customers and Concentrations of Risk

Revenues by customer location are summarized as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
United States of America	$	14,174,112	$	12,036,590	$	37,009,301	$	33,631,332
Europe		750,470		1,215,218		3,018,099		3,829,809
Other		127,815		226,955		448,615		564,784
	$	15,052,397	$	13,478,763	$	40,476,015	$	38,025,925

Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Teva	$	7,663,701	$	5,522,996	$	17,043,954	$	18,513,972
AMAG		1,767,702		2,369,950		6,338,275		3,275,832
McKesson		2,339,238		1,946,261		6,333,080		5,501,810
AmerisourceBergen		1,470,268		1,156,566		4,323,013		3,658,453
Ferring		723,502		1,246,300		3,018,098		3,960,689

7.	Net Loss Per Share

Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share because their effect was anti-dilutive totaled 15,084,877 and 14,100,835 at September 30, 2017 and 2016, respectively.

8.	Recent Accounting Pronouncements

Accounting Pronouncements Recently Adopted

In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11, Simplifying the Measurement of Inventory. The new standard changed the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. The Company adopted this standard during the first quarter of 2017, and the adoption did not have an impact on the consolidated results of operations, cash flows or financial position of the Company.

In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The Company adopted ASU 2016-09 effective January 1, 2017, and the adoption did not have a significant impact on the Company’s consolidated financial statements. As required under previous GAAP, the Company had estimated forfeitures in determining its periodic compensation costs related to share-based awards. Upon adoption of the new standard, the Company has elected to recognize forfeitures as they occur, and recorded a cumulative effect adjustment to accumulated deficit and additional paid-in capital of $97,000, the net of which had no impact on the Company’s consolidated results of operations, cash flows or financial position.

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). This new standard eliminates Step 2 from the goodwill impairment test. ASU 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. ASU 2017-04 still allows the option to perform a qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The Company early adopted this standard effective January 1, 2017 and will apply the standard prospectively for its annual goodwill impairment tests. The adoption of the standard did not have an impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), supplemented with a number of subsequent amendments issued by the FASB and collectively referred to herein as “ASU 2014-09”. This guidance requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard creates a five-step model that requires a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied. This guidance also requires an entity to disclose sufficient information to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative information is required about contract balances and remaining performance obligations, significant judgments made in determining the timing of satisfaction of performance obligations (over time or at a point in time), and estimates made in determining the transaction price and amounts allocated to performance obligations.

The Company continues to monitor and evaluate the impact the adoption of this standard will have on its consolidated financial statements and has performed an initial review of its major contracts with customers. Based on the initial reviews, the Company believes the adoption of the new standard may accelerate the timing of revenue recognition for certain product sales and development revenue under certain license, development and supply agreements, and will require management to estimate and potentially recognize certain variable revenue streams such as royalties and profit sharing arrangements earlier at an amount it believes will not be subject to significant reversal.

cannot currently be quantified, as the calculation of such will depend upon the open contracts and performance obligations as of the transition date. No significant changes to business processes or systems are currently expected to be necessary, as the processes and controls used in recording revenue transactions are largely manual.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). This new standard requires entities to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. This new standard is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those annual periods and early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements and currently expects that most of its operating lease commitments will be subject to the new standard and recognized as operating lease liabilities and right-of-use assets in the statement of financial position upon adoption of ASU 2016-02.

In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”), which provides guidance on determining which changes to terms and conditions of share-based awards require an entity to apply modification accounting under Topic 718. This new standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods, and early adoption is permitted. The adoption of ASU 2017-09 is not expected to have a significant impact on the Company’s consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-05, Other Income – Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). The amendments clarify that an entity should identify each distinct nonfinancial asset or in-substance nonfinancial asset promised to a counterparty and derecognize each asset when a counterparty obtains control of it. ASU 2017-05 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods. The Company is currently evaluating the potential impact, if any, on its consolidated financial statements upon the adoption of ASU 2017-05 and expects to adopt the standard effective January 1, 2018.

9.	Subsequent Events

ZOMAJET™ Asset Purchase Agreement

On October 10, 2017, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Ferring to sell the worldwide rights, including certain assets, related to the ZOMAJET™ needle-free auto injector device (the “Product”) for a total purchase price of $14.5 million.

The purchase price is to be paid in four installments consisting of the following: a $2.0 million upfront payment received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million payable upon delivery of certain documentation and satisfaction of certain conditions primarily related to Product manufacturing; a third installment of $4.75 million payable upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million upon Ferring’s receipt of the CE Mark needed to continue to commercialize the Product in certain territories and the final transfer of certain Product-related inventory, equipment and agreements to Ferring (the “Completion Date”), which is expected to occur by the end of 2018.

The Company will continue to manufacture and supply ZOMAJET™ devices until the Completion Date and will receive payment for devices manufactured and supplied to its partners, and a royalty on net product sales, in accordance with the existing license and supply agreements.

Litigation

On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell (“Smith”), Case No. 3:17-cv-08945-MAS-DEA, on behalf of a putative class of persons who purchased or otherwise acquired Antares securities between December 21, 2016 and October 12, 2017, inclusive, asserting claims for purported violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against Antares, Robert F. Apple and Fred M. Powell. The Smith complaint contends that defendants made false and/or misleading statements and/or failed to disclose that: (i) Antares had provided insufficient data to the FDA in connection with the NDA for XYOSTED^TM; and (ii) accordingly, Antares had overstated the approval prospects for XYOSTED^TM. Motions for the appointment of Lead Plaintiff are due December 22, 2017. The Company believes that the claims in the Smith action lack merit and intends to defend them vigorously.

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Certain statements in this report, including statements in the management’s discussion and analysis section set forth below, may be considered “forward-looking statements” as that term is defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the words “expect,” “estimate,” “plan”, “project,” “anticipate,” “should,” “intend,” “may,” “will,” “believe,” “continue” or other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and product development. In particular, these forward-looking statements include, among others, statements about:

•

our expectations regarding commercialization and sales of OTREXUP^® (methotrexate) injection;

•

our expectations regarding the ability of our partner Teva Pharmaceutical Industries, Ltd.’s (“Teva”) to successfully commercialize Sumatriptan Injection USP;

•

our expectations regarding the continued development of XYOSTED^TM (testosterone enanthate) injection for testosterone replacement therapy and our intentions to request a meeting with the United States Food and Drug Administration (“FDA”) to further evaluate the deficiencies raised in the Complete Response Letter (“CRL”) to our New Drug Application (“NDA”) submitted for XYOSTED^TM (testosterone enanthate) injection to agree upon a path forward for a potential approval, and to work closely with the FDA to understand the nature of the deficiencies and resolve such deficiencies;

•

our expectations about our ability to adequately respond to the deficiencies in the CRL received from the FDA for XYOSTED^TM, whether any such response will be accepted by the FDA, our ability and timing to resubmit the NDA for XYOSTED^TM, and whether FDA approval will be received for XYOSTED^TM;

•

our expectations regarding continued product development with Teva, and potential FDA approval of the VIBEX^® Epinephrine Pen (“epinephrine auto injector”), teriparatide disposable pen injector and exenatide disposable pen injector, and Teva’s ability to successfully commercialize each of those products;

•

our expectations regarding continued product development with our partner AMAG Pharmaceuticals, Inc. (“AMAG”), and potential FDA approval of an auto injector for Makena^®;

•

our expectations about the timing and successful completion of the sale of our worldwide rights, including certain assets, for the ZOMAJET™ needle-free auto injector device to Ferring International Center S.A. (“Ferring”);

•

our expectations about the timing and outcome of pending or potential claims and litigation, including without limitation, the Smith complaint;

•

our expectations regarding trends in pharmaceutical drug delivery characteristics;

•

our anticipated continued reliance on third-party contract manufacturers to manufacture our products;

•

our anticipated continued reliance on third parties to provide certain services for our products including logistics, warehousing, distribution, invoicing, contract administration and chargeback processing;

•

our sales and marketing plans;

•

our product development and commercialization plans regarding our other products and product candidates;

•

the timing and results of our clinical trials, research and development projects;

•

our future cash flow and our ability to support our operations;

•

our estimates and expectations regarding the sufficiency of our cash resources, anticipated capital requirements and our need for and ability to obtain additional financing;

•

our expectations and estimates with regard to current accounting practices and the potential impact of new accounting pronouncements; and

•

our expectations regarding our financial and operating results for the year ending December 31, 2017.

Forward-looking statements are based on assumptions that we have made in light of our industry experience as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. As you read and consider this report, you should understand that these statements are not guarantees of

performance results. Forward-looking statements involve known and unknown risks, uncertainties and assumptions, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of the future about which we cannot be certain. Many factors may affect our ability to achieve our objectives, including:

•

changes or delays in the regulatory review and approval process;

•

our inability to adequately or timely respond to or address deficiencies identified in a CRL from the FDA;

•

delays in product introduction and marketing or interruptions in supply;

•

a decrease in business from our major customers and partners;

•

our inability to compete successfully against new and existing competitors or to leverage our research and development capabilities and our marketing capabilities;

•

our inability to effectively market our products and services or obtain and maintain arrangements with our customers, partners and manufacturers;

•

our inability to obtain adequate third-party payor coverage of our marketed products;

•

our inability to effectively protect our intellectual property;

•

costs associated with future litigation and the outcome of such litigation;

•

our inability to attract and retain key personnel;

•

adverse economic and political conditions; and

•

our ability to obtain additional financing, reduce expenses or generate funds when necessary.

In addition, you should refer to the “Risk Factors” sections of this report and of our Annual Report on Form 10-K for the year ended December 31, 2016 for a discussion of other factors that may cause our actual results to differ materially from those described by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements contained in this report will prove to be accurate and, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.

We encourage readers of this report to understand forward-looking statements to be strategic objectives rather than absolute targets of future performance. Forward-looking statements speak only as of the date they are made. We do not intend to update publicly any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made or to reflect the occurrence of unanticipated events except as required by law. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, if at all.

The following discussion and analysis, the purpose of which is to provide investors and others with information that we believe to be necessary for an understanding of our financial condition, changes in financial condition and results of operations, should be read in conjunction with the financial statements, notes thereto and other information contained in this report.

Overview

Company and Product Overview

Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Our strategy is to identify new or existing approved drug formulations and apply our drug delivery technology to enhance the drug compounds and delivery methods. We develop, manufacture and commercialize, for ourselves or with partners, novel therapeutic products using our advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Our subcutaneous injection technology platforms include the VIBEX^® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. We have a portfolio of proprietary and partnered products, including approved commercial products and several product candidates in advanced stages of development and under active FDA review. We have formed significant strategic alliances and partnership arrangements with industry leading pharmaceutical companies including Teva, AMAG and Ferring.

We market and sell our proprietary product OTREXUP^® (methotrexate) injection, which was launched in the U.S. in February 2014. OTREXUP^® is the first FDA-approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. To date, we have received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP^®.

With our commercialization partner Teva, we launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. We received FDA approval of our Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex^® STATdose Pen^®, in December 2015. Sumatriptan Injection USP represents the Company’s first ANDA approval of a complex generic and second product approved using the VIBEX^® auto injector platform and is commercialized and distributed by Teva under the terms of a license, supply and distribution arrangement.

We also have two gel-based products that are commercialized through our partners pursuant to licensing arrangements and make reusable, needle-free injection devices that administer injectable drugs, which are currently marketed primarily through our partner Ferring, for use with human growth hormone.

On October 10, 2017, we entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Ferring to sell the worldwide rights, including certain assets, related to the ZOMAJET™ needle-free auto injector device (the “Product”) for a total purchase price of $14.5 million.

We will continue to manufacture and supply ZOMAJET™ devices until the Completion Date and will receive payment for devices and a royalty on net product sales in accordance with the existing license and supply agreements.

Overview of Clinical, Regulatory and Product Development Activities

We are developing XYOSTED^TM (testosterone enanthate) injection for testosterone replacement therapy, and submitted a 505 (b)(2) New Drug Application (“NDA”) to the FDA in December 2016. The NDA submission was accepted for standard review by the FDA and assigned a Prescription Drug User Fee Act (“PDUFA”) target date for completion of its review by October 20, 2017.

On September 22, 2017, we received FDA labeling comments with regard to the NDA and responded to the comments on September 29, 2017. On October 11, 2017, we received a letter from the FDA stating that, as part of its ongoing review of the NDA, the FDA has identified deficiencies that preclude the continuation of the discussion of labeling and postmarketing requirements/commitments. On October 20, 2017, we received a Complete Response Letter (“CRL”) from the FDA regarding our NDA for XYOSTED^TM, which identified two deficiencies and indicated that the NDA cannot be approved in its current form. We are assessing the content of the CRL, including the information that may be needed to resolve the deficiencies, and intend to work closely with the FDA to determine the appropriate responses to the deficiencies noted in the CRL.

The clinical basis of our NDA submission for XYOSTED^TM included a multi-center, phase 3 clinical study (“QST-13-003”) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot^® auto injector in adult males diagnosed with testosterone deficiency, in which positive top-line pharmacokinetic results that showed that the primary endpoint for this study was achieved. Based upon a written response we received from the FDA related to our clinical development program for XYOSTED^TM, we conducted an additional supplemental safety study QST-15-005. The study included a screening phase, a treatment titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. In September 2016, we announced the successful completion of the QST-15-005 study. The results of these two studies formed the clinical basis of our NDA submission for XYOSTED^TM and are further discussed in the “Research and Development Programs” section below.

The CRL for XYOSTED^TM identified two deficiencies related to the clinical data. Based on findings in studies QST-13-003 and QST-15-005, the FDA is concerned that XYOSTED^T^M could cause a clinically meaningful increase in blood pressure. In addition, the CRL also raised a concern regarding the occurrence of depression and suicidality. The Company anticipates that the next step will be

to request a meeting with the FDA to further evaluate the deficiencies raised and to agree upon a path forward for a potential approval of XYOSTED^TM.

We are collaborating with Teva on a VIBEX^® auto injector pen containing epinephrine used for the treatment of severe allergic reactions (anaphylaxis). Teva submitted an amendment to the VIBEX^® epinephrine pen ANDA in December 2014 and received a Complete Response Letter from the FDA in February 2016 in which, according to Teva, the FDA identified certain major deficiencies. Teva has disclosed that they submitted a response to this Complete Response Letter. We continue to work with Teva toward a potential approval of the epinephrine auto injector pen ANDA, which remains under active review at the FDA.

Our other combination product development projects in collaboration with Teva include a multi-dose pen for a generic form of BYETTA^® (exenatide injection) for the treatment of diabetes, and another multi-dose pen for a generic form of Forteo^® (teriparatide [rDNA origin] injection) for the treatment of osteoporosis. Teva filed an ANDA for exenatide, which was accepted by the FDA in October 2014 and is currently under FDA review. In 2016, we announced that Teva had settled the patent litigation with AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and Amylin Pharmaceuticals, LLC (collectively “AstraZeneca”) relating to certain AstraZeneca U.S. patents and their drug, BYETTA^® (exenatide). AstraZeneca and Teva entered into a settlement and license agreement pursuant to which AstraZeneca granted Teva a license to manufacture and commercialize the generic version of BYETTA^® described in Teva’s ANDA. The settlement allows Teva to commercialize their exenatide product in the U.S. beginning October 15, 2017 or earlier under certain circumstances. Teva also filed an ANDA for a generic version of Forteo^® (teriparatide [rDNA origin] injection), which was accepted by the FDA in February 2016 and is currently under review. In response to Teva’s paragraph IV certification contained in Teva’s ANDA for teriparatide, Eli Lilly & Co (“Lilly”) filed a lawsuit against Teva alleging infringement of six U.S. patents related to Forteo^® (teriparatide [rDNA origin] injection) resulting in a 30-month stay in FDA approval of the ANDA. The stay will expire in August 2018 unless the litigation is resolved sooner. Teva also successfully concluded a decentralized procedure registration process in Europe. According to Teva, the Public Assessment Report for the decentralized procedure has been published and the product was filed in 17 countries, which addresses the majority of the market value in Europe.

In partnership with AMAG, we are currently developing a variation of our VIBEX^® QuickShot^® subcutaneous auto injector for use with AMAG’s Makena^® (hydroxyprogesterone caproate injection) for the treatment of pre-term birth. Under a license, development and supply agreement, AMAG is responsible for the clinical development and preparation, submission and maintenance of all regulatory applications, the manufacture and supply of the drug, and the marketing, sale and distribution of the product. We are responsible for the design and development of the auto-injection device, the manufacturing and supply of the device, and assembly and packaging of the final product. AMAG initiated a pharmacokinetic (“PK”) study in October 2016 and disclosed positive top line results of the study in February 2017. According to AMAG, the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena^® compared to intra muscular injection. AMAG submitted its sNDA for the Makena^®subcutaneous auto injector in April 2017, which was accepted by the FDA and given a PDUFA target action date of February 14, 2018.

Critical Accounting Policies

Our management’s discussion and analysis of our results of operations and financial condition is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”.) The preparation of our financial statements in accordance with GAAP requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses. We have identified certain of our significant accounting policies that we believe to be the most critical to the understanding our results of operations and financial condition because they require the most subjective and complex judgments. The following supplements our critical accounting policies, which are fully described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2016.

Revenue Recognition—OTREXUP^®

We sell OTREXUP^® in packages of four pre-filled, single-dose disposable auto injectors to wholesale pharmaceutical distributors, our customers, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. We began detailing OTREXUP^® to health care professionals in February 2014.

Prior to the first quarter of 2017, we could not reliably estimate expected returns of OTREXUP^® at the time of shipment given our limited sales history of the product. Accordingly, the recognition of revenue was deferred on product shipments until the rights of return no longer existed, which occurred at the earlier of the time that OTREXUP^® units were dispensed through patient prescriptions or expiration of the right of return of the product. Patient prescriptions dispensed were estimated using third-party market prescription data.

In the first quarter of 2017, we determined we had developed sufficient historical information to reasonably estimate future returns of OTREXUP^®and began recognizing revenue upon delivery to the distributors, net of estimated returns. Accordingly, we recognized $1,297,054 in revenue for product shipped to distributors in previous periods but not previously recognized as revenue at the time of shipment, net of the returns allowance established during the first quarter of 2017. We also recognized $254,425 of related product costs in the first quarter of 2017. The net impact of these changes resulted in a decrease to net loss of $1,042,629, or less than $0.01 per share, for the nine months ended September 30, 2017.

Results of Operations

We reported net losses of $5,452,521 and $6,120,983 for the three months ended September 30, 2017 and 2016, respectively, and $13,028,382 and $19,838,556 for the nine months ended September 30, 2017 and 2016, respectively. Net loss per share was $0.03 for the three months ended September 30, 2017 as compared to $0.04 for the three months ended September 30, 2016, and $0.08 and $0.13 for the nine months ended September 30, 2017 and 2016, respectively. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The following is an analysis and discussion of our operations for the three and nine months ended September 30, 2017 as compared to the same periods in 2016.

Revenues

	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016
OTREXUP^®	$	4,623,326	$	3,904,329	$	13,110,489	$	11,024,394
Auto injector and pen injector devices		7,946,313		5,943,786		14,489,839		15,836,179
Needle-free injector devices and components		757,886		1,201,725		3,108,422		3,720,316
Total product sales		13,327,525		11,049,840		30,708,750		30,580,889
Development revenue		1,485,091		2,101,203		7,894,640		6,466,974
Licensing revenue		19,486		38,618		1,057,204		128,040
Royalties		220,295		289,102		815,421		850,022
Total revenue	$	15,052,397	$	13,478,763	$	40,476,015	$	38,025,925

Total revenue for the three months ended September 30, 2017 and 2016 was $15,052,397 and $13,478,763, respectively, representing an increase in total revenue of 12% on a comparative basis. Revenue for the nine months ended September 30, 2017 was $40,476,015 as compared to $38,025,925 for the nine months ended September 30, 2016, representing an increase of 6%. The following is a detailed discussion of the components of and changes in revenue.

OTREXUP^®

For the three months ended September 30, 2017 and 2016, we recognized revenue of $4,623,326 and $3,904,329, respectively, from sales of OTREXUP^®, which is presented net of estimated product returns and sales allowances. The increase in revenue for the three months ended September 30, 2017 as compared to the three months ended September 30, 2016 was driven by an increase in shipments to distributors and an underlying growth in prescriptions dispensed. However, as discussed in our “Critical Accounting Policies” above, we began recognizing revenue upon delivery to distributors, net of estimated returns, in the first quarter of 2017. Prior to the first quarter of 2017, due to lack of sufficient sales and returns history, revenue was initially deferred upon shipment to distributors and recognized based on estimated prescriptions dispensed or expiration of customer right of return. This change in estimation and recognition method may affect the comparability of revenues on a period over period basis.

We recognized revenue of $13,110,489 and $11,024,394 from OTREXUP^® sales for the nine months ended September 30, 2017 and 2016, respectively. The increase in OTREXUP^® revenue for the nine months ended September 30, 2017 as compared with the same period in 2016 included the recognition of $1,297,054 in previously deferred revenue. If we underestimate or overestimate product returns for a given period, adjustments to revenue may be necessary in future periods.

Auto injector and pen injector devices

Product sales of auto injector devices were $7,946,313 and $5,943,786 for the three months ended September 30, 2017 and 2016, respectively, and $14,489,839 and $15,836,179 for the nine months ended September 30, 2017 and 2016, respectively. We manufacture devices and sell fully assembled and packaged Sumatriptan Injection USP product to Teva. We also sell pre-launch

quantities of injector devices for use with Teva’s generic epinephrine pen, and auto injector devices for use with AMAG’s Makena^® in anticipation of potential approvals and launch of these products.

The increase in auto injector product revenue for the three months ended September 30, 2017 as compared to the same period in 2016 was principally attributable to an increase in shipments of Sumatriptan Injection USP and the related profit earned under the margin sharing arrangement with Teva. Revenue from auto injector sales for the three months ended September 30, 2017 was principally attributable to sumatriptan product sold to Teva, totaling $6,400,000 including the profit sharing recognized during the quarter, and approximately $1,000,000 and $500,000 of pre-launch quantities of devices for use with Makena^®and epinephrine, respectively. Revenue for the three months ended September 30, 2016 included approximately $3,400,000 in shipments of sumatriptan product at cost, $1,400,000 in auto-injector devices for use with Makena^® and $1,100,000 of pre-launch quantities of auto injector devices sold to Teva for use with their generic epinephrine product.

The decrease in product revenue from sales of auto injectors for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 was a result of a significant reduction in sales of pre-launch quantities of auto-injectors for use with Teva’s generic epinephrine product. As previously discussed, Teva’s ANDA for the epinephrine auto injector is under review by the FDA and Teva is targeting a launch in early 2018. The decrease in revenue from pre-launch shipments of epinephrine auto injectors was partially offset by a significant increase in sales of Sumatriptan Injection USP, which was launched in June 2016.

Needle-free injector devices and components

Our revenue from reusable needle-free injector devices and disposable components was $757,886 and $1,201,725 for the three months ended September 30, 2017 and 2016, respectively, and $3,108,422 and $3,720,316 for the nine months ended September 30, 2017 and 2016 respectively. These revenues were generated primarily from sales to Ferring, which sells our needle-free injector for use with its hGH products in Europe, Asia and the U.S. We do not control our partners’ sales volume or inventory levels of our injectors and components, which can cause fluctuations in our product sales in comparative periods.

On October 10, 2017, we announced the sale of the worldwide rights related to the ZOMAJET™ needle-free auto injector device and expect the transaction to be completed by the end of 2018. During the transfer and completion period, we will continue to manufacture and supply ZOMAJET™ devices until the completion date and will receive payment for devices and a royalty on net product sales in accordance with the existing license and supply agreements.

Development revenue

Development revenue typically represents amounts earned under arrangements with partners for which we develop new products on their behalf. Frequently, we receive up-front and milestone payments from our partners that are initially deferred and recognized as revenue over a development period or upon completion of defined deliverables. Development revenue was $1,485,091 and $2,101,203 for the three months ended September 30, 2017 and 2016, respectively, and was $7,894,640 and $6,466,974 for the nine months ended September 30, 2017 and 2016, respectively. The increase in development revenue recognized for the nine months ended September 30, 2017 as compared to 2016 was primarily a result of increases in development activities with AMAG for the Makena^® auto injector product offset by reductions in revenue for development activities with Teva in connection with the epinephrine auto injector and pen injector programs. The decrease in development revenue for the three months ended September 30, 2017 as compared to the same period in 2016 was primarily a result of lower development revenue related to the Makena^® auto injector development program with AMAG and the exenatide pen injector program with Teva.

Licensing Revenue

Licensing revenue represents amounts received from partners for the right to use certain intellectual property. Generally, the up-front or milestone payments received were initially deferred and recognized in revenue over the license period. We recognized $19,486 and $38,618 for the three months ended September 30, 2017 and 2016, respectively and $1,057,204 and $128,040 for the nine months ended September 30, 2017 and 2016, respectively. The significant increase in licensing revenue recognized in the nine months ended September 30, 2017 is due to the recognition of $1,000,000 in licensing fees previously received and initially deferred due to potential contractual refund rights of the customer under certain circumstances. During the second quarter of 2017, the License, Supply and Distribution Agreement with Teva for Sumatriptan Injection USP was amended such that the refund provisions relating to the licensing fee was removed. Accordingly, we recognized the deferred revenue in income, as the license had been delivered and there were no remaining obligations related to the license granted.

Royalties

Royalty revenue was $220,295 and $289,102 for the three months ended September 30, 2017 and 2016, respectively and $815,421 and $850,022 for the nine months ended September 30, 2017 and 2016, respectively. We receive royalties from Ferring related to needle-free injector device sales and on sales of ZOMACTON^TM in the U.S., and on sales of gel-based products commercialized through partners.

Cost of Revenue and Gross Profit

The following table summarizes our total revenue, cost of revenue and gross profit:

	Three months ended September 30,						Nine months ended September 30,
	2017			2016			2017			2016
Total revenue	$	15,052,397		$	13,478,763		$	40,476,015		$	38,025,925
Total cost of revenue		8,522,897			8,033,721			20,359,052			22,127,560
Gross profit	$	6,529,500		$	5,445,042		$	20,116,963		$	15,898,365
Gross profit percentage		43	%		40	%		50	%		42	%

Our gross profit was $6,529,500 and $20,116,963 for the three and nine months ended September 30, 2017, respectively, as compared to $5,445,042 and $15,898,365 for the three and nine months ended September 30, 2016, respectively. The increase in our gross profit for the nine months ended September 30, 2017 was primarily attributable to the recognition of $1,000,000 in licensing revenue previously deferred, for which there was no associated costs, the recognition of previously deferred revenue related to OTREXUP^® sales, and other changes in our product revenue and cost of sales, which is summarized in the following table and discussed below.

	Three months ended September 30,						Nine months ended September 30,
	2017			2016			2017			2016
Product sales	$	13,327,525		$	11,049,840		$	30,708,750		$	30,580,889
Cost of product sales		7,600,180			7,206,280			16,681,689			18,670,363
Product gross profit	$	5,727,345		$	3,843,560		$	14,027,061		$	11,910,526
Product gross margin percentage		43	%		35	%		46	%		39	%

Product gross profit increased in the three months ended September 30, 2017 as compared to the three months ended September 30, 2016, primarily due to sales of OTREXUP^®and to sales of Sumatriptan Injection USP, which is initially sold at cost to Teva, and profit recognized from the margin sharing arrangement in trailing periods. The increase in product gross profit for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 included the $1,042,629 net impact of recognizing previously deferred revenue and related product costs for OTREXUP^® as described in “Critical Accounting Policies” above, and sales of Sumatriptan Injection USP, which was launched in June 2016. These increases were offset by the reduction in epinephrine auto injector device sales and the associated cost of sales. The cost of product sales includes product acquisition costs from third-party manufacturers and internal manufacturing overhead expenses.

Other variations in revenue, cost of revenue and gross profit are attributable to our development activities, which fluctuate depending on the mix of development projects in progress and stages of completion in each period. The cost of development revenue consists primarily of direct external costs, some of which may have been previously incurred and deferred. The cost of development revenue in each period was primarily related to revenue recognized under the Teva auto injector and pen injector programs and development of the Makena^® auto injector with AMAG.

Research and Development

Research and development expenses consist of external costs for clinical studies and analysis activities, design work and prototype development, FDA fees, personnel costs and other general operating expenses associated with our research and development activities. Research and development expenses were $3,289,445 and $5,958,550 for the three months ended September 30, 2017 and 2016, respectively, and $9,535,089 and $15,554,599 for the nine months ended September 30, 2017 and 2016, respectively. The decrease in research and development costs on a comparative basis is primarily due to a decrease in external clinical and development costs related to XYOSTED^TM for testosterone replacement therapy. We completed clinical trials and submitted our NDA for XYOSTED^TM to the FDA in the fourth quarter of 2016. On October 20, 2017, we received a CRL from the FDA regarding our NDA

for XYOSTED^TM. See further discussion of our research and development activities related to XYOSTED^TM in the “Research and Development Programs” section below.

Selling, General and Administrative

Selling, general and administrative expenses were $8,185,865 and $5,622,937 for three months ended September 30, 2017 and 2016, respectively and $23,013,130 and $20,240,635 for the nine months ended September 30, 2017 and 2016, respectively. The overall increase in selling, general and administrative expenses was primarily attributable to an increase in sales and marketing costs associated with the preparation for a potential launch of XYOSTED^TM.

Liquidity and Capital Resources

At September 30, 2017, we had cash and cash equivalents of $27,433,489 and short-term investments of $9,976,984. Our principal liquidity needs are to fund our research and development activities and for the payment of other operating expenses. We have not historically generated, and do not currently expect to generate, enough revenue or operating cash flow to support or grow our operations and we continue to operate primarily by raising capital. Our primary sources of liquidity are proceeds from equity offerings and debt issuance. We believe that the combination of our current cash and cash equivalents, short-term investments, projected product sales, development revenue milestones and royalties will provide us with sufficient funds to meet our obligations and support operations through at least the next twelve months from the date of this report.

Long-Term Debt Financing

On June 6, 2017, we entered into a loan and security agreement for a term loan of up to $35,000,000 (the “Term Loan”), the proceeds of which are to be used for working capital and general corporate purposes. The first advance of $25,000,000 was funded upon execution of the Loan Agreement on June 6, 2017. Under the terms of the Loan Agreement, we may, but are not obligated to, request one or more additional advances of at least $5,000,000 not to exceed $10,000,000 in the aggregate, subject to the company achieving certain corporate milestones and satisfying customary conditions. The option to request additional advances must be exercised prior to September 30, 2018. Payments under the Loan Agreement are interest only until the first principal payment is due on August 1, 2019, provided that the interest only period may be extended to February 1, 2020 if certain corporate milestones are achieved. The Loan Agreement also requires us to pay a fee equal to 4.25% of the total original principal amount of all term loan advances (“End of Term Charge”), which is due upon repayment of the Term Loan at either maturity or earlier repayment.

At the Market Common Stock Offering Program

On August 11, 2017, we entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which we may offer and sell, from time to time at our sole discretion, shares of common stock having an aggregate offering price of up to $30,000,000 through Cowen as our sales agent and/or principal. Cowen may sell the common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended. We will pay Cowen a commission of 3.0% of the gross sales proceeds of any common stock sold through Cowen under the Sales Agreement. We are not obligated to make any sales of our common stock under the Sales Agreement and as of the date of this report we have not sold any common stock pursuant to the Sales Agreement.

Net Cash Flows from Operating Activities

Operating cash inflows are generated primarily from product sales, license and development fees and royalties. Operating cash outflows consist principally of expenditures for manufacturing costs, personnel costs, general and administrative expenses, research and development projects, and sales and marketing activities. Fluctuations in cash used in operating activities are primarily a result of the timing of cash receipts and disbursements. Net cash used in operating activities was $15,482,269 for the nine months ended September 30, 2017 and $11,696,233 for the nine months ended September 30, 2016. For the nine months ended September 30, 2017, the increase in net cash used in operating activities was primarily driven by our inventory build, changes in accounts receivable and deferred revenue, and other changes in operating assets and liabilities due to timing of cash receipts and cash payments.

Net Cash Flows from Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2017 was $10,926,425 as compared to net cash provided by investing activities of $7,617,569 for the nine months ended September 30, 2016. The net cash outflow for the nine months ended September 30, 2017, was attributable to purchases of investment securities totaling $9,963,978 and payments for capital expenditures and patent acquisition costs, while the net cash inflow for the nine months ended September 30, 2016 was attributable to

maturities of investment securities of $12,000,000, offset by payments for capital expenditures and patent acquisition costs totaling $4,278,643.

Net Cash Flows from Financing Activities

Cash flow provided by financing activities was $26,127,902 for the nine months ended September 30, 2017, and was primarily attributable to the receipt of $25,000,000 proceeds from debt issuance and $1,670,149 cash proceeds received from the exercise of stock options offset by payments of debt issuance costs and tax withholding payments in connection with settlement of share-based awards. The net cash used in financing activities was $40,025 for the nine months ended September 30, 2016, included the receipt of $24,000 in proceeds from the exercise of stock options and $64,000 remitted to taxing authorities in connection with net-share settled awards for which we withheld shares equivalent to the value of the employees’ minimum statutory obligation for the applicable income and other employment taxes.

Contractual Obligations

The following table presents our contractual obligations and the related payments, including interest, due by period as of September 30, 2017:

	Payments Due by Period
			Less than		1 - 3		3 - 5		More than
	Total		1 year		years		years		5 years
Long-Term Debt Obligations	$	33,706,453	$	2,217,882	$	12,930,373	$	18,558,198	$	—
Operating Lease Obligations		1,882,226		629,600		896,282		356,344		—
Total	$	35,588,679	$	2,847,482	$	13,826,655	$	18,914,542	$	—

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, including any arrangements with any structured finance, special purpose or variable interest entities.

Research and Development Programs

We conduct clinical, regulatory, formulation development, parenteral device development and commercial development activities for internal and partnered products. The following is a discussion of our significant research and development programs.

XYOSTED^TM (testosterone enanthate) Injection (Formerly referred to as VIBEX^® QuickShot^® Testosterone or “QST”).

We are developing XYOSTED^TM for self-administered weekly injections of testosterone enanthate for clinically diagnosed testosterone deficient men requiring testosterone replacement therapy.

On December 5, 2012, we conducted a pre-IND (Investigational New Drug application) meeting with the FDA as part of preparing to initiate clinical development of XYOSTED^TM, establishing an agreed upon clinical path forward. In September 2013, we announced that the first patients were dosed in a clinical study evaluating the PK profile of testosterone enanthate administered weekly by subcutaneous injection at doses of 50 mg and 100 mg via the XYOSTED^TM auto injector device in testosterone deficient adult males. The study enrolled 39 patients at nine investigative sites in the U.S. On February 20, 2014, we announced positive top line results of this study that showed that the primary endpoint was achieved in that XYOSTED^TM treatment resulted in most patients achieving average levels of testosterone within the normal range from the first dose onward.

On November 3, 2014, we announced that the last patient had been enrolled in a double-blind, multiple-dose, phase III study (QST-13-003) to evaluate the efficacy and safety of XYOSTED^TM administered subcutaneously once each week to testosterone-deficient adult males. Patients enrolled in this study had a documented diagnosis of hypogonadism or testosterone deficiency defined as having testosterone levels below 300 ng/dL. The study includes a screening phase, a treatment titration and efficacy phase and an extended treatment phase. One hundred fifty patients were enrolled in this study. Patients meeting all eligibility criteria were assigned to receive a starting dose of XYOSTED^TM once weekly for six weeks. Adjustments to dose could be made at week seven based upon the week six pre-dose blood level. The efficacy of XYOSTED^TM and dose adjustment to regulate testosterone levels were evaluated after 12 weeks of treatment.

On February 25, 2015, we announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in QST-13-003. The protocol for the study required that at the week 12 endpoint: (i) at least 75% of all patients’ C_avg are within the normal range of 300 to 1100 ng/dL, with a lower limit of a 95% 2-sided confidence interval of greater than or equal to 65%, (ii) at least 85% of patients’ C_max are less than1500 ng/dL and (iii) no more than 5% of patients had a C_max greater than 1800 ng/dL. The primary endpoint of the population that received one or more doses of XYOSTED^TM was met by 139 out of 150 patients, equating to 92.7% with a 95% confidence interval of 87.3% to 96.3%. Among the 137 patients that completed all 12 weeks of dosing and PK sampling, 98.5% were within the pre-defined range. The top-line results of the PK study are summarized in the table below.

Population/Analysis	C_avgLower limit of the 95% 2-sided C. I.			C_avg% in range 300 – 1100 ng/dL n (%)		C_max <1500 ng/dL n (%)		C_max >1800 ng/dL n (%)
Primary analysis* N=150		87.3	%	139 (92.7	%)	137 (91.3	%)**		0	%
Completers N=137		94.8	%	135 (98.5	%)	137 (100	%)		0	%
Protocol-Required Outcomes		≥65	%	75	%	≥85	%		≤5	%

*	All patients with 1 or more doses, C_avg 0-168 hours post week 12 injection or last measured concentration carried forward

**	Patients without a C_maxdetermination at week 12 are assigned above 1500 ng/dL

Overall, the regimen demonstrated a mean (± standard deviation) steady state concentration of testosterone of 553.3 ± 127.3 ng/dL at 12 weeks. Participants in the study remained on XYOSTED^TM and were followed for an additional 40 weeks for the collection of safety data.

After we initiated study QST-13-003, but before we announced positive top-line pharmacokinetic results in February 2015, we received written recommendations from the FDA related to our clinical development program for XYOSTED^TM. The recommendations received were in response to various clinical, chemistry, manufacturing and controls and user study submissions that we made through November 2014. We believe that we had already factored many of the recommendations cited in the advice letter into the protocol of the ongoing QST-13-003 study and into the protocols for planned human use studies as a result of guidance provided by the FDA at the May 2014 Type C meeting. Based on a single reported occurrence of hives in our phase 2 study, the FDA recommended that we create a larger safety database, including approximately 350 subjects exposed to XYOSTED^TM with approximately 200 subjects exposed for six months and approximately 100 subjects exposed for a year. We assessed the FDA’s comments in the advice letter and their impact on the timing of the filing of a NDA for XYOSTED^TM with the FDA. Based on the number of subjects in previous studies and in the current QST-13-003 study, we concluded that we would need additional subjects exposed to XYOSTED^TM for six months. The timing and design of the study to obtain the additional subjects and data required was determined based on further discussion with the FDA. We submitted our response to the FDA’s written recommendations in early March 2015.

In October 2015, we announced that the last patient in study QST-13-003 received their week 52 treatment, which marked the end of the treatment phase of this study. In March 2016, we announced that the pharmacokinetic results of QST-13-003 were final and reported the results from the 52-week safety study. The safety population, defined as patients who received at least one dose of study drug, was comprised of 150 patients. The most common adverse reactions (incidence ≥5%) in this phase 3 study were increased hematocrit, hypertension, increased prostate-specific antigen, upper respiratory tract infection, sinusitis, injection site bruising and headache. Serious adverse events (SAE’s) reported included one case each of worsening depression, vertigo and suicide. None of the SAE’s were considered to be related to the study drug by the investigators, however the Company determined that the case of suicide could not be ruled out as potentially being related to study drug. There have been no reported adverse events consistent with urticaria (hives), pulmonary oil micro embolism (“POME”), anaphylaxis or major adverse cardiovascular events in this study.

In May 2015, we received an additional written update from the FDA related to our clinical development program for XYOSTED^TM. Based on that update received from the FDA, we concluded there was an agreed upon path forward for the completion of an additional study to support the filing of a NDA for XYOSTED^TM. In June 2015, we finalized and submitted the protocol for the study, and in August 2015, we enrolled the first patients in the study, which is known as QST-15-005. The study was a dose-blind, multiple-dose, concentration controlled 26-week supplemental safety and pharmacokinetic study of XYOSTED^TM, which included a screening phase, a treatment titration phase, and a treatment phase for evaluation of safety and tolerability assessments including laboratory assessments, adverse events and injection site assessment. Patients meeting all eligibility criteria were assigned to receive 75 mg of XYOSTED^TM once weekly for six weeks. According to the protocol, adjustments to dose could be made at week seven based upon the week six C_trough value. XYOSTED^TM was provided to clinical sites at dosage strengths of 100 mg, 75 mg and 50 mg to be utilized in dose titration.

In early November 2015, the Company announced that enrollment was complete in study QST-15-005. The safety population, defined as patients who received at least one dose of the study drug, consisted of 133 patients dosed with XYOSTED^TM. In June 2016, we announced that the last patient had completed treatment under the 26-week safety and pharmacokinetic phase 3 study QST-15-005, and in September 2016 we announced the results of the study. The most common adverse reactions (incidence ≥5%) in the QST-15-005 study were increased hematocrit, upper respiratory tract infection and injection site ecchymosis. There were four patients with treatment emergent SAE’s, which included one patient with transient visual impairment determined not to be drug related, one patient with appendicitis that was not drug related and one patient with deep vein thrombosis (“DVT”). The investigator attributed DVT as possibly drug related, which is consistent with known testosterone class SAE’s. The fourth patient had multiple hospitalizations related to septic arthritis and coronary artery disease, with a complicated clinical course post-angioplasty. These multiple reported events from the fourth patient were deemed not to be drug related. There were no reported adverse events consistent with urticaria, POME or anaphylaxis. The safety data collected also included an assessment of pain. Of the 965 injections assessed, pain was reported one time. In that instance, the pain reported was classified as mild.

Based upon the completion of our clinical and development work and the results of the studies detailed above, we submitted a 505 (b) (2) New Drug Application for XYOSTED^TM to the FDA in December 2016. The NDA submission was accepted for standard review by the FDA and assigned a PDUFA target date for completion of its review by October 20, 2017.

On September 22, 2017, we received FDA labeling comments with regard to the NDA and responded to the comments on September 29, 2017. On October 11, 2017, we received a letter from the FDA stating that, as part of its ongoing review of the NDA, the FDA has identified deficiencies that preclude the continuation of the discussion of labeling and postmarketing requirements/commitments. On October 20, 2017, we received the CRL from the FDA regarding our NDA for XYOSTED^TM, which identified two deficiencies and indicated that the NDA cannot be approved in its current form. We are assessing the content of the CRL, including the information that may be needed to resolve the deficiencies, and intend to work closely with the FDA to determine the appropriate responses to the deficiencies noted in the CRL.

The CRL for XYOSTED^TM identified two deficiencies related to the clinical data. Based on findings in studies QST-13-003 and QST-15-005, the FDA is concerned that XYOSTED^TM could cause a clinically meaningful increase in blood pressure. In addition, the CRL also raised a concern regarding the occurrence of depression and suicidality. The Company anticipates that the next step will be to request a meeting with the FDA to further evaluate the deficiencies raised and to agree upon a path forward for a potential approval of XYOSTED^TM.

Device Development Projects. We, along with our pharmaceutical partners, are engaged in research and development activities related to our VIBEX^® disposable pressure assisted auto injectors and our disposable pen injectors. We have signed license agreements with Teva for our VIBEX^® system for a product containing epinephrine and for our pen injector devices for use with generic versions of BYETTA^® (exenatide) and Forteo^® (teriparatide). We also have a license, development and supply agreement with AMAG for our auto injector device for use with its drug Makena^®. The development programs consist of determination of the device design, development of prototype tooling, production of prototype devices for testing and clinical studies, and development of commercial tooling and assembly. We expect development related to these products to continue, however, the development timelines are generally controlled by our partners and the extent of near-term and future development will be dependent on decisions made by our partners. The following is a summary of the development stages for each of the products in development with Teva and AMAG.

VIBEX^® auto injector with Makena^®(hydroxyprogesterone caproate injection)

We are in the process of developing a variation of our VIBEX^® QuickShot^® auto injector for use with the progestin hormone drug Makena^® under a license, development and supply agreement with AMAG. Under this arrangement, AMAG is responsible for the clinical development and preparation, and submission and maintenance of all regulatory applications. We are responsible for the design and development of the auto-injection device.

AMAG initiated a PK study for the Makena^®auto injector in October 2016 and announced positive top-line results of the study in February 2017. According to AMAG, the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena^® compared to intra muscular injection. AMAG submitted its sNDA for the Makena^®subcutaneous auto injector in April 2017, which was accepted by the FDA and given a PDUFA target action date of February 14, 2018.

VIBEX^® auto injector with epinephrine

We, in collaboration with Teva, have developed a VIBEX^® auto injector device for a product containing epinephrine. Teva is responsible for development work on the drug epinephrine, and we are responsible for development of the device. Teva filed an ANDA for the VIBEX^® epinephrine pen as a generic substitute of Mylan’s branded product, EpiPen^®, which was accepted by the FDA, and amended in December 2014. We have scaled up the commercial tooling and molds for this product and delivered pre-

launch quantities of the product in anticipation of a potential approval and launch. However, Teva received a Complete Response Letter to its ANDA for the VIBEX^® epinephrine pen from the FDA in February 2016 in which, according to Teva, the FDA identified certain major deficiencies. Teva has disclosed that they submitted a response to the FDA’s Complete Response Letter. We continue to work with Teva toward a potential approval of the epinephrine auto injector pen ANDA, which remains under active review at the FDA.

Exenatide disposable pen injector

We have designed and produced a pen injector product for use with exenatide for Teva. Teva filed an ANDA for a generic version of BYETTA^®, which was accepted by the FDA in October 2014 and is currently under review. Teva settled patent litigation with AstraZeneca relating to certain AstraZeneca U.S. patents and their drug, BYETTA^® (exenatide). AstraZeneca and Teva entered into a settlement and license agreement pursuant to which AstraZeneca granted Teva a license to manufacture and commercialize the generic version of BYETTA^® described in Teva’s ANDA. The settlement allows Teva to commercialize their exenatide product in the U.S., assuming FDA approval, beginning October 15, 2017 or earlier under certain circumstances.

Teriparatide disposable pen injector

We have designed and produced a multi-dose disposable pen injector for use with teriparatide for Teva and have delivered devices for a drug stability program to support a regulatory filing. Teva is developing this product for use in both Europe and the U.S. with the European clinical/regulatory team leading the development.

Teva filed an ANDA for a generic version of Forteo^® (teriparatide [rDNA origin] injection), which was accepted by the FDA and is currently under review. In response to Teva’s paragraph IV certification contained in Teva’s ANDA for teriparatide, Lilly filed a lawsuit against Teva alleging infringement of six U.S. patents related to Forteo^® (teriparatide [rDNA origin] injection) resulting in a 30-month stay in FDA approval of the ANDA. The stay will expire in August 2018 unless the litigation is resolved sooner. Teva also successfully concluded a decentralized procedure registration process in Europe. According to Teva, the Public Assessment Report for the decentralized procedure has been published and the product was filed in 17 countries, which addresses the majority of the market value in Europe.

Other Research and Development Costs. In addition to our development of XYOSTED^TM and our device development projects with Teva and AMAG, we incur direct costs associated with other internal research and development projects and indirect costs that include personnel costs, administrative and other operating costs related to managing our research and development activities.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to foreign exchange rate fluctuations of the Swiss Franc to the U.S. dollar as the financial position and operating results of our subsidiaries in Switzerland are translated into U.S. dollars for consolidation. Our exposure to foreign exchange rate fluctuations also arises from transferring funds to our Swiss subsidiaries in Swiss Francs. In addition, we have exposure to exchange rate fluctuations between the Euro and the U.S. dollar in connection with a licensing agreement with Ferring, under which certain products sold to Ferring and royalties are denominated in Euros. Most of our product sales, including a portion of our product sales to Ferring, and our development and licensing fees and royalties are denominated in U.S. dollars, thereby significantly mitigating the risk of exchange rate fluctuations on trade receivables. We do not currently use derivative financial instruments to hedge against exchange rate risk. The effect of foreign exchange rate fluctuations on our financial results for the periods ended September 30, 2017 was not material.

We may be exposed to interest rate risk and interest rate fluctuations as a result of our long-term debt financing we obtained on June 6, 2017. Our Term Loan, with a current outstanding principal of $25,000,000, accrues interest at a calculated prime-based variable rate with a maximum interest rate of 9.50%. The calculated prime-based variable rate was 8.75% at September 30, 2017. An increase to the maximum interest rate of 9.50% would result in additional incremental annual interest expense of $187,500.

Item 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s management, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. The evaluation was performed to determine whether the Company’s disclosure controls and procedures have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time

periods specified in the Securities and Exchange Commission’s rules and is accumulated and communicated to management, including the Company’s principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report were effective.

Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II - OTHER INFORMATION

Item 1.

LEGAL PROCEEDINGS

On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell (“Smith”), Case No. 3:17-cv-08945-MAS-DEA, on behalf of a putative class of persons who purchased or otherwise acquired Antares securities between December 21, 2016 and October 12, 2017, inclusive, asserting claims for purported violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 against Antares, Robert F. Apple and Fred M. Powell. The Smith complaint contends that defendants made false and/or misleading statements and/or failed to disclose that: (i) Antares had provided insufficient data to the FDA in connection with the NDA for XYOSTED^TM; and (ii) accordingly, Antares had overstated the approval prospects for XYOSTED^TM. Motions for the appointment of Lead Plaintiff are due December 22, 2017. The company believes that the claims in the Smith action lack merit and intends to defend them vigorously.

Item 1A.

RISK FACTORS

In addition to the risk factors and other information contained in this report, you should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Risks Related to Our Operations

Timing and results of clinical trials to demonstrate the safety and efficacy of products as well as the FDA’s approval of products are uncertain.

Drug development is an inherently risky and uncertain process. Before obtaining regulatory approvals for the sale of any new product candidates, we and our partners must demonstrate through preclinical studies and clinical trials that the product is safe and effective for each intended use. Preclinical and clinical studies may fail to demonstrate the safety and effectiveness of a product. Likewise, we and our partners may not be able to demonstrate through clinical trials that a product candidate’s therapeutic benefits outweigh its risks. Even promising results from preclinical and early clinical studies do not always accurately predict results in later, large scale trials. A failure to demonstrate safety and efficacy could or would result in the failure to obtain regulatory approvals.

The rate of patient enrollment sometimes delays completion of clinical studies. There is substantial competition to enroll patients in clinical trials and such competition has delayed clinical development of our products in the past. For example, patients may not enroll in clinical trials at the rate expected or patients may drop out after enrolling in the trials or during the trials. Delays in planned patient enrollment can result in increased development costs and delays in regulatory approval. In addition, we rely on

collaboration partners that may control or make changes in trial protocol and design enhancements, or encounter clinical trial compliance-related issues, which may also delay clinical trials. Product supplies may be delayed or be insufficient to treat the patients participating in the clinical trials, or manufacturers or suppliers may not meet the requirements of the FDA or foreign regulatory authorities, such as those relating to cGMP. We and our partners may also experience delays in obtaining, or we and our partners may not obtain, required initial and continuing approval of our clinical trials from institutional review boards, FDA, or other applicable regulatory authorities. We cannot assure you that we or our partners will not experience delays or undesired results in these or any other clinical trials. Clinical trials may also be suspended, placed on hold, or terminated by us, institutional review boards, FDA, or other applicable regulatory authorities for a number of reasons, including failure to comply with the applicable regulatory requirements, including GCPs, and issues involving subject safety.

We cannot assure you that the FDA or foreign regulatory agencies will approve, clear for marketing or certify any products developed by us or our partners, on a timely basis, if at all, or, if granted, that such approval will not subject the marketing of our products to certain limits or other costly and burdensome requirements. Such limits and requirements may include warnings, including black box warnings, limitations on the indicated use, including the applicable population, contraindications, Risk Evaluation and Mitigation Strategies, and post-approval studies and/or monitoring. The FDA or foreign regulatory authorities may not agree with the assessment by us or our clinical partners of the clinical data or they may interpret it differently. Such regulatory authorities may require additional or expanded clinical trials. On October 20, 2017, we received from the FDA the CRL for XYOSTED^TM which identified two deficiencies and indicated that the XYOSTED^TM NDA cannot be approved in its current form. We are assessing the content of the CRL, including the information that may be needed to resolve the deficiencies, which may include additional clinical trials. We intend to work closely with the FDA to determine the appropriate responses to the deficiencies noted in the CRL.

Any limitation on use imposed by the FDA or delay in or failure to obtain FDA approvals or clearances of products developed by us and our partners would adversely affect the marketing of these products and our ability to generate product revenue, which would adversely affect our financial condition and results of operations.

Before obtaining regulatory approvals for certain generic products, we and our partners must conduct limited clinical or other trials to show comparability to the branded products. A failure to obtain satisfactory results in these trials would prevent us from obtaining required regulatory approvals.

Risks Related to Regulatory Matters

The CRL for XYOSTED^TM identified two deficiencies and indicated that the XYOSTED^TM NDA cannot be approved in its current form. To the extent that we are unable to resolve these deficiencies in a timely manner or at all, or if we fail to obtain, or have delays in obtaining, regulatory approvals for any of our other products and product candidates, our business, financial condition and results of operations may be materially adversely affected.

XYOSTED^TM and our other products and product candidates are subject to extensive and rigorous government regulation by the FDA and other foreign regulatory agencies. The FDA regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import and export of pharmaceutical and medical device products. Failure to comply with FDA and other applicable regulatory requirements may, either before or after product approval, subject us to administrative or judicially imposed sanctions.

In the United States, the FDA regulates drug and device products under the Federal Food, Drug, and Cosmetic Act (FFDCA), and its implementing regulations. XYOSTED^TM, as well as other of our products and product candidates are subject to regulation by the FDA as combination products, which means they are composed of both a drug product and device product. If marketed individually, each component would therefore be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination of the product’s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of XYOSTED^TM and our other products and product candidates, the primary mode of action is attributable to the drug component of the product, which means that the Center of Drug Evaluation and Research (CDER) has primary jurisdiction over its pre-market development and review. Following product approval, however, our products may be subject to regulation under FDA’s drug and device requirements.

We are not permitted to market our product candidates, including XYOSTED^TM, in the United States unless and until we obtain regulatory approval from the FDA. To market the product in the United States, we must submit to the FDA and obtain FDA approval of a marketing application. We have historically used FDA’s 505(b)(2) NDA and ANDA pathways. A 505(b)(2) NDA must be supported by extensive clinical and preclinical data, as well as extensive information regarding chemistry, manufacturing and controls, or CMC, to demonstrate the safety and effectiveness of the applicable product candidate. An ANDA must be supported by studies demonstrating that the product candidate is bioequivalent to the reference listed drug, as well as extensive information

regarding CMC. The number and types of preclinical studies and clinical trials that will be required varies depending on the product candidate, the approval pathway, the disease or condition that the product candidate is designed to target and the regulations applicable to any particular product candidate.

Despite the time and expense associated with preclinical and clinical studies, failure can occur at any stage, and we could encounter problems that cause us to repeat or perform additional preclinical studies, CMC studies or clinical trials. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including, failure to receive FDA or IRB authorization to begin a trial, negative or inconclusive results, slow or insufficient subject enrollment, failure to obtain adequate clinical supply of product candidates, and failure by us, our partners, Contract Research Organizations, and clinical trial sites to follow the applicable regulatory requirements, including GCPs. The FDA and similar foreign authorities could also delay, limit or deny approval of a product candidate for many reasons, including because they:

•

may not deem a product candidate to be adequately safe and effective;

•

may not find the data from preclinical studies, CMC studies and clinical trials to be sufficient to support a claim of safety and efficacy;

•

may interpret data from preclinical studies, CMC studies and clinical trials significantly differently than we do;

•

may not approve the manufacturing processes or facilities associated with our product candidates;

•

may not agree with the pathway that we have chosen for our product candidates, requiring us to pursue more difficult approval pathways, including full NDAs;

•

may find that our reliance on a reference listed drug for an ANDA or 505(b)(2) application or literature for a 505(b)(2) application is not appropriate;

•

may not agree with the design and/or implementation of our clinical and/or pre-clinical studies;

•

may require us to conduct additional clinical and/or pre-clinical studies;

•

may change approval policies (including with respect to our product candidates’ class of drugs) or adopt new regulations; or

•

may not accept a submission due to, among other reasons, the content or formatting of the submission.

Significant delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow competitors, to bring products to market before we do.

Additionally, based on the written recommendations from the FDA related to our clinical development program for XYOSTED^TM, we launched a supplemental safety study QST-15-005 with additional participants, which we completed in 2016 in support of our NDA submission for XYOSTED^TM. However, the FDA may have additional recommendations or require further trials and the timing, cost and design of any such study could negatively affect our business if we incur significant costs or delays. Products of this nature may carry with them the need to monitor safety in an on-going manner, called a Risk Evaluation Mitigation Strategy, or REMS. The REMS for testosterone products is well-defined, and a class-labeling letter has been issued to all approved testosterone replacement products that will likely include being part of a clinical outcomes trial intended to explore cardiovascular risks.

Undesirable side effects caused by any product candidate that we develop, a lack of bioequivalence for ANDA product candidates, and/or an inability to demonstrate product candidate efficacy could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications or cause us to evaluate the future of our development programs.

Undesirable side effects could also interrupt, delay, or halt clinical trials. The regulatory review and approval process is lengthy, expensive and inherently uncertain.

In December 2016, we submitted the XYOSTED^TM NDA which was accepted for filing by FDA in February 2017. On October 20, 2017, we received from the FDA the CRL for XYOSTED^TM which identified two deficiencies and indicated that the XYOSTED^TM NDA cannot be approved in its current form. We are assessing the content of the CRL, including the information that may be needed to resolve the deficiencies, which may include additional clinical trials. We intend to work closely with the FDA to determine the appropriate responses to the deficiencies noted in the CRL. However, there can be no assurance that we will be able to resolve these deficiencies, and, even if we resolve these deficiencies, the FDA may find that overall, the benefits of XYOSTED^TM do not outweigh the risks identified in the FDA’s CRL.

Failure to obtain, or delays in obtaining, regulatory approvals may:

•

adversely affect the commercialization of the current version of XYOSTED^TM or any products that we develop in the future;

•

adversely affect the commercialization of the current version of XYOSTED^TM or any products that we develop in the future;

•

impose additional costs on us;

•

diminish any competitive advantages that may be attained; and

•

adversely affect our ability to generate revenues.

We may never receive approval for certain of our product candidates, and even if our product candidates are approved, the approval may be subject to limitations on the indicated uses for which the products may be marketed, distribution restrictions, or to other conditions of approval; may contain significant safety warnings, including boxed warnings, contraindications, and precautions; may not be approved with label statements necessary or desirable for successful commercialization; or may contain requirements for costly post‑market testing and surveillance or other requirements, including REMS, to monitor the safety or efficacy of the products. Moreover, any future actions or inquiries by the FDA with respect to the reference listed drug may require that we make changes to our labeling or, possibly, withdraw the product from the market. Any of the foregoing may impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.

Risks Related to Our Common Stock

The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors.

The trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including our historical and anticipated operating results, our financial situation, clinical trial results, announcements of technological innovations or new products by us, our partners or our competitors, our ability or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions. Some of these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading in our stock, regardless of our financial condition, results of operations, business or prospect. Among the factors that may cause the market price of our common stock to fluctuate are the risks described in this “Risk Factors” section and other factors, including:

•

fluctuations in our quarterly operating results or the operating results of our competitors;

•

variance in our financial performance from the expectations of investors;

•

our ability to address the deficiencies identified in the CRL for XYOSTED^TMand ultimately receive product approval;

•

changes in the estimation of the future size and growth rate of our markets;

•

changes in accounting principles or changes in interpretations of existing principles, which could affect our financial results;

•

failure of our products to achieve or maintain market acceptance or commercial success;

•

conditions and trends in the markets we serve;

•

changes in general economic, industry and market conditions;

•

success of competitive products and services;

•

changes in market valuations or earnings of our competitors;

•

changes in our pricing policies or the pricing policies of our competitors;

•

announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors;

•

changes in legislation or regulatory policies, practices or actions;

•

the commencement or outcome of litigation involving our company, our general industry or both;

•

recruitment or departure of key personnel;

•

changes in our capital structure, such as future issuances of securities or the incurrence of debt;

•

actual or expected sales of our common stock by our stockholders; and

•

the trading volume of our common stock.

In addition, the stock markets, in general, the NASDAQ Capital Market and the market for specialty pharmaceutical companies in particular, may experience a loss of investor confidence. Such loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, financial condition or results of operations. These broad market and industry factors may materially harm the market price of our common stock and expose us to securities class action litigation. For example, on October 23, 2017, Randy Smith filed a complaint in the District of New Jersey on behalf of a putative class of persons who purchased or otherwise acquired Antares securities against Antares, Robert F. Apple and Fred M. Powell. Litigation, even if unsuccessful, could be costly to defend and divert management’s attention and resources, which could further materially harm our financial condition and results of operations.

Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3.

DEFAULT UPON SENIOR SECURITIES

None.

Item 4.

MINE SAFETY DISCLOSURES

Not applicable.

Item 5.

OTHER INFORMATION

None.

Item 6.

EXHIBITS

(a)	Exhibit Index

Exhibit No.		Description

31.1#		Certificate of the Chief Executive Officer of Antares Pharma, Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2#		Certificate of the Chief Financial Officer of Antares Pharma, Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1##		Certificate of the Chief Executive Officer of Antares Pharma, Inc. required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2##		Certificate of the Chief Financial Officer of Antares Pharma, Inc. required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS#		XBRL Instance Document

101.SCH#		XBRL Taxonomy Extension Schema Document

101.CAL#		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB#		XBRL Taxonomy Extension Label Linkbase Document

101.PRE#		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF#		XBRL Taxonomy Extension Definition Document

#	Filed herewith.

##	Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ANTARES PHARMA, INC.

November 7, 2017		/s/ Robert F. Apple
		Robert F. Apple
		President and Chief Executive Officer
		(Principal Executive Officer)

November 7, 2017		/s/ Fred M. Powell
		Fred M. Powell
		Senior Vice President and Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 atrs-ex311_21.htm EX-31.1 atrs-ex311_21.htm

Exhibit 31.1

CERTIFICATIONS

I, Robert F. Apple, certify that:

1.	I have reviewed this report on Form 10-Q for the fiscal quarter ended September 30, 2017 of Antares Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2017

/s/ Robert F. Apple

Robert F. Apple

President and Chief Executive Officer

EX-31.2 3 atrs-ex312_20.htm EX-31.2 atrs-ex312_20.htm

Exhibit 31.2

CERTIFICATIONS

I, Fred M. Powell, certify that:

1.	I have reviewed this report on Form 10-Q for the fiscal quarter ended September 30, 2017 of Antares Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2017

/s/ Fred M. Powell

Fred M. Powell

Senior Vice President and Chief Financial Officer

EX-32.1 4 atrs-ex321_19.htm EX-32.1 atrs-ex321_19.htm

Exhibit 32.1

ANTARES PHARMA, INC.

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

The undersigned, Robert F. Apple, the Chief Executive Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2017 (the “Report”).

The undersigned hereby certifies that:

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of the 7th day of November, 2017.

/s/ Robert F. Apple

Robert F. Apple

President and Chief Executive Officer

EX-32.2 5 atrs-ex322_18.htm EX-32.2 atrs-ex322_18.htm

Exhibit 32.2

ANTARES PHARMA, INC.

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

The undersigned, Fred M. Powell, the Chief Financial Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2017 (the “Report”).

The undersigned hereby certifies that:

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of the 7th day of November, 2017.

/s/ Fred M. Powell

Fred M. Powell

Senior Vice President and Chief Financial Officer

EX-101.INS 6 atrs-20170930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure atrs:Installment 0001016169 2017-01-01 2017-09-30 0001016169 2017-11-01 0001016169 2017-09-30 0001016169 2016-12-31 0001016169 2017-07-01 2017-09-30 0001016169 2016-07-01 2016-09-30 0001016169 2016-01-01 2016-09-30 0001016169 2015-12-31 0001016169 2016-09-30 0001016169 us-gaap:PerformanceSharesMember 2017-01-01 2017-09-30 0001016169 atrs:OtrexupMember 2017-01-01 2017-03-31 0001016169 atrs:OtrexupMember 2017-01-01 2017-09-30 0001016169 atrs:OtrexupMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001016169 atrs:OtrexupMember 2016-12-30 2016-12-31 0001016169 atrs:TevaMember 2017-01-01 2017-09-30 0001016169 atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-06-06 0001016169 atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-06-05 2017-06-06 0001016169 atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-01-01 2017-09-30 0001016169 atrs:HerculesCapitalIncMember atrs:TermLoanMember us-gaap:MinimumMember 2017-06-06 0001016169 atrs:HerculesCapitalIncMember atrs:TermLoanMember us-gaap:MaximumMember 2017-06-06 0001016169 us-gaap:PrimeRateMember atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-06-05 2017-06-06 0001016169 atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-09-30 0001016169 us-gaap:MinimumMember atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-01-01 2017-09-30 0001016169 us-gaap:MaximumMember atrs:HerculesCapitalIncMember atrs:TermLoanMember 2017-01-01 2017-09-30 0001016169 us-gaap:MaximumMember atrs:CowenAndCompanyLimitedLiabilityCompanyMember atrs:SalesAgreementMember 2017-08-10 2017-08-11 0001016169 atrs:CowenAndCompanyLimitedLiabilityCompanyMember atrs:SalesAgreementMember 2017-08-10 2017-08-11 0001016169 atrs:AmendedAndRestatedTwoThousandEightEquityCompensationPlanMember 2017-09-30 0001016169 atrs:AmendedAndRestatedTwoThousandEightEquityCompensationPlanMember 2017-01-01 2017-09-30 0001016169 us-gaap:EmployeeStockOptionMember atrs:AmendedAndRestatedTwoThousandEightEquityCompensationPlanMember 2017-01-01 2017-09-30 0001016169 us-gaap:EmployeeStockOptionMember atrs:AmendedAndRestatedTwoThousandEightEquityCompensationPlanMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2017-09-30 0001016169 us-gaap:EmployeeStockOptionMember atrs:LongTermIncentiveProgramMember 2017-01-01 2017-09-30 0001016169 us-gaap:RestrictedStockUnitsRSUMember atrs:LongTermIncentiveProgramMember 2017-01-01 2017-09-30 0001016169 us-gaap:PerformanceSharesMember atrs:LongTermIncentiveProgramMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001016169 us-gaap:PerformanceSharesMember atrs:LongTermIncentiveProgramMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001016169 us-gaap:PerformanceSharesMember 2016-12-31 0001016169 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001016169 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001016169 us-gaap:PerformanceSharesMember 2017-09-30 0001016169 us-gaap:RestrictedStockUnitsRSUMember 2017-09-30 0001016169 us-gaap:PerformanceSharesMember 2016-09-30 0001016169 us-gaap:PerformanceSharesMember 2015-09-30 0001016169 us-gaap:PerformanceSharesMember 2016-01-01 2016-09-30 0001016169 us-gaap:PerformanceSharesMember 2015-01-01 2015-09-30 0001016169 us-gaap:PerformanceSharesMember atrs:LongTermIncentiveProgramMember 2017-01-01 2017-09-30 0001016169 us-gaap:PerformanceSharesMember atrs:LongTermIncentiveProgramMember 2016-01-01 2016-09-30 0001016169 us-gaap:RestrictedStockUnitsRSUMember atrs:LongTermIncentiveProgramMember 2016-01-01 2016-09-30 0001016169 country:US 2017-07-01 2017-09-30 0001016169 country:US 2016-07-01 2016-09-30 0001016169 country:US 2017-01-01 2017-09-30 0001016169 country:US 2016-01-01 2016-09-30 0001016169 us-gaap:EuropeMember 2017-07-01 2017-09-30 0001016169 us-gaap:EuropeMember 2016-07-01 2016-09-30 0001016169 us-gaap:EuropeMember 2017-01-01 2017-09-30 0001016169 us-gaap:EuropeMember 2016-01-01 2016-09-30 0001016169 atrs:OtherGeographicalAreaMember 2017-07-01 2017-09-30 0001016169 atrs:OtherGeographicalAreaMember 2016-07-01 2016-09-30 0001016169 atrs:OtherGeographicalAreaMember 2017-01-01 2017-09-30 0001016169 atrs:OtherGeographicalAreaMember 2016-01-01 2016-09-30 0001016169 atrs:TevaMember 2017-07-01 2017-09-30 0001016169 atrs:TevaMember 2016-07-01 2016-09-30 0001016169 atrs:TevaMember 2016-01-01 2016-09-30 0001016169 atrs:AMAGPharmaceuticalsIncMember 2017-07-01 2017-09-30 0001016169 atrs:AMAGPharmaceuticalsIncMember 2016-07-01 2016-09-30 0001016169 atrs:AMAGPharmaceuticalsIncMember 2017-01-01 2017-09-30 0001016169 atrs:AMAGPharmaceuticalsIncMember 2016-01-01 2016-09-30 0001016169 atrs:McKessonMember 2017-07-01 2017-09-30 0001016169 atrs:McKessonMember 2016-07-01 2016-09-30 0001016169 atrs:McKessonMember 2017-01-01 2017-09-30 0001016169 atrs:McKessonMember 2016-01-01 2016-09-30 0001016169 atrs:AmerisourceBergenMember 2017-07-01 2017-09-30 0001016169 atrs:AmerisourceBergenMember 2016-07-01 2016-09-30 0001016169 atrs:AmerisourceBergenMember 2017-01-01 2017-09-30 0001016169 atrs:AmerisourceBergenMember 2016-01-01 2016-09-30 0001016169 atrs:FerringMember 2017-07-01 2017-09-30 0001016169 atrs:FerringMember 2016-07-01 2016-09-30 0001016169 atrs:FerringMember 2017-01-01 2017-09-30 0001016169 atrs:FerringMember 2016-01-01 2016-09-30 0001016169 atrs:AccountingStandardsUpdate201609Member 2017-01-01 2017-09-30 0001016169 atrs:AssetPurchaseAgreementMember atrs:ZOMAJETMember atrs:FerringMember us-gaap:SubsequentEventMember 2017-10-10 0001016169 atrs:AssetPurchaseAgreementMember atrs:ZOMAJETMember atrs:FerringMember us-gaap:SubsequentEventMember 2017-10-09 2017-10-10 10-Q false 2017-09-30 2017 Q3 ATRS ANTARES PHARMA, INC. 0001016169 --12-31 Accelerated Filer 156674504

27433489

27714588

9976984

10146966

9073173

7942376

5326962

1213507

1773446

1680208

1376299

58393530

45264468

17296719

17867412

1630785

2044608

1095355

53778

53607

78470167

66325450

8245154

7884983

6394379

5872846

2842801

6149087

17482334

19906916

24791214

200000

1200000

42473548

21106916

1564259

1551677

301703929

297826433

-266570874

-253445306

-700695

-714270

35996619

45218534

78470167

66325450

0.01

3000000

0.01

300000000

156425904

155167677

156425904

155167677

13327525

11049840

30708750

30580889

1485091

2101203

7894640

6466974

19486

38618

1057204

128040

220295

289102

815421

850022

15052397

13478763

40476015

38025925

7600180

7206280

16681689

18670363

922717

827441

3677363

3457197

8522897

8033721

20359052

22127560

6529500

5445042

20116963

15898365

3289445

5958550

9535089

15554599

8185865

5622937

23013130

20240635

11475310

11581487

32548219

35795234

-4945810

-6136445

-12431256

-19896869

625938

794129

119227

15462

197003

58313

-5452521

-6120983

-13028382

-19838556

-0.03

-0.04

-0.08

-0.13

156400702

155060811

155851639

154952060

-3621

2632

13575

-7820

-5456142

-6118351

-13014807

-19846376

2371453

1886823

1520197

1371538

-22600

-17785

45600

66406

18347

16638

-10913

1069614

624232

2615414

999158

299825

-2922527

-559939

762413

701704

3308607

549929

-146376

-4308571

1156309

-15482269

-11696233

9963978

878855

4278643

83592

103788

12000000

-10926425

7617569

25000000

293538

1670149

24071

248709

64096

26127902

-40025

-307

1440

-281099

-4117249

32898676

28781427

92674

552556

6160 23369

<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> 5.</td> <td valign="top"> Share-Based Compensation</td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards.  All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan.  The maximum number of shares authorized for issuance under the amended and restated Plan is 32,200,000 and the maximum number of shares of stock that may be granted to any one employee for qualified performance-based compensation during a calendar year is 4,000,000 shares.  Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant.  The term of each option is ten years and the options typically vest in quarterly installments over a three-year period with a minimum vesting period of one year.  As of September 30, 2017, the Plan had approximately 6,400,000 shares available for grant. Stock option exercises are satisfied through the issuance of new shares. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2017:      <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,313,909</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,975,667</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.67</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,062,693</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.57</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(833,033</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.68</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,393,850</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,631,780</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,043,282</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,880,581</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The per share weighted average fair values of all options granted during the nine months ended September 30, 2017 and 2016 were estimated as $1.62 and $0.54, respectively, on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of the Company’s stock price.  The weighted average expected life is based on both historical and anticipated employee behavior.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annualized volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.4%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.6%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average expected life, in years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September 30, 2017, stock option exercises resulted in cash proceeds to the Company of $1,670,149 and the issuance of 1,062,693 shares of common stock.  Stock option exercises resulted in proceeds of $24,071 and the issuance of 21,492 shares of common stock in the nine months ended September 30, 2016. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $1,680,437 and $1,572,710 of compensation expense related to stock options for the nine months ended September 30, 2017 and 2016, respectively, and $692,834 and $505,663 for the three months ended September 30, 2017 and 2016, respectively.  As of September 30, 2017, there was approximately $4,500,000 of total unrecognized compensation cost related to non-vested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.1 years. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Long Term Incentive Program <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s Board of Directors has approved a long term incentive program (“LTIP”) for the benefit of the Company’s senior executives.  Pursuant to the LTIP, the Company’s senior executives have been awarded stock options, restricted stock units (“RSU”) and performance stock units (“PSU”) with targeted values based on values granted to similarly situated senior executives in the Company’s peer group. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The RSUs vest in three equal annual installments.  The PSU awards made to the senior executives vest and convert into shares of the Company’s common stock based on the Company’s attainment of certain performance goals as established by the Company’s Board of Directors over a performance period, which is typically three to five years. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Stock Units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,347,289</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">822,658</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">689,180</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">689,180</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested/settled</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287,508</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(502,308</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,464</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr style="height:12.95pt;"> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,534,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,156,866</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, 2016 and 2015, the LTIP awards include PSUs that may be earned based on the Company’s total shareholder return (“TSR”) relative to the Nasdaq Biotechnology Index (“NBI”) at the end of the performance period.  The performance period is January 1, 2015 to December 31, 2017 for the 2015 award, January 1, 2016 to December 31, 2018 for the 2016 award and January 1, 2017 to December 31, 2019 for the 2017 award.  Depending on the outcome of the performance goal, a recipient may ultimately earn a number of shares greater or less than their target number of shares granted, ranging from 0% to 150% of the PSUs granted. The fair values of the TSR PSUs granted was determined using a Monte Carlo simulation and utilized the following inputs and assumptions:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017 Award</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016 Award</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015 Award</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Closing stock price on grant date</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.66</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.18</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance period starting price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term of award (in years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.59</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.97</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.83</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value per TSR PSU</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The performance period starting price is measured as the average closing price over the last 20 trading days prior to the performance period start. The Monte Carlo simulation model also assumed correlations of returns of the prices of the Company’s common stock and the common stocks of the NBI companies and stock price volatilities of the NBI companies.  The fair value of the target number of shares that can be earned under the TSR PSUs is being recognized as compensation expense over the performance period.   <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with PSU awards, the Company recognized compensation expense of $239,995 and $11,331 for the nine months ended September 30, 2017 and 2016, respectively.  Compensation expense recognized in connection with RSU awards was $451,021 and $302,782 for the nine months ended September 30, 2017 and 2016, respectively. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued in connection with LTIP awards that vested in the nine months ended September 30, 2017 and 2016 were net-share settled such that the Company withheld shares with a value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld to satisfy tax obligations were 97,586 and 65,575 in the nine months ended September 30, 2017 and 2016, respectively, and were based on the fair value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $248,709 and $64,096 in the nine months ended September 30, 2017 and 2016, respectively, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.</div>

<div> Inventories <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located.  Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations.  The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,000,000 and $900,000 at September 30, 2017 and December 31, 2016, respectively.  Inventories consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw material</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,491</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,357,554</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,429,075</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,458,752</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,755,396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,942,376</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326,962</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition — OTREXUP® <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company began detailing OTREXUP® to health care professionals in February 2014. OTREXUP® is sold in packages of four pre-filled, single-dose disposable auto injectors to wholesale pharmaceutical distributors, its customers, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the first quarter of 2017, the Company could not reliably estimate expected returns of OTREXUP® at the time of shipment given its limited sales history of the product. Accordingly, the recognition of revenue was deferred on product shipments until the rights of return no longer existed, which occurred at the earlier of the time OTREXUP® units were dispensed through patient prescriptions or expiration of the right of return of the product. Patient prescriptions dispensed were estimated using third-party market prescription data.   <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2017, the Company determined it had developed sufficient historical information to reasonably estimate future returns of OTREXUP® and began recognizing revenue, net of estimated returns, upon delivery to the distributors. As a result, the Company recognized an additional $1,297,054 for product shipped to distributors in previous periods that was not previously recognized as revenue at the time of shipment, net of the returns allowance established in the first quarter of 2017. The Company also recognized $254,425 of related product costs that had been previously deferred.  The net impact of these changes resulted in a decrease in net loss of $1,042,629, less than $0.01 per share, for the nine months ended September 30, 2017. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales revenue for OTREXUP® is presented net of estimated returns and product sales allowances for wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs. The estimated product returns reserve was $650,000 as of September 30, 2017 and zero at December 31, 2016.  Product sales allowances were $1,986,553 as of September 30, 2017 and $1,540,488 as of December 31, 2016. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product Sales Allowances <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, it may be necessary to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Product sales allowances include: <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Wholesaler Distribution Fees. Distribution fees are paid to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Prompt Pay Discounts. The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chargebacks. The Company provides discounts to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rebates. The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients.  Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated percentages of product sold to qualified patients.  Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patient Discount Programs. The Company offers discount card programs to patients for OTREXUP® in which patients receive discounts on their prescriptions that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on historical redemption experience and on estimated levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition — Sumatriptan Injection <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under a license, supply and distribution agreement with Teva for an auto-injector product containing sumatriptan, the Company produces devices and assembles product for shipment to Teva, and Teva is responsible for commercial distribution and sale of the product.  The Company is compensated, and recognizes revenue, at cost for shipments of product delivered to Teva.  The Company is also entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the quarter in which the commercial sales are made by Teva.   <p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sumatriptan Injection USP was launched for commercial sale in June 2016.  Initially, given the limited access to sales data and the 45-day lag in reporting of the profit split from Teva, management was not able to estimate the profit margin the Company expected to receive from commercial sales made by Teva at the time of sale.  Accordingly, prior to the third quarter of 2017, revenue from the profit sharing arrangement was recognized in the period following the commercial sales by Teva when amounts were reported and paid to the Company.  Beginning in the third quarter of 2017, management determined it had developed sufficient history and is now able to obtain additional sales information in order to reasonably estimate and recognize revenue from the profit sharing arrangement when product is sold by Teva.</div>

<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11, Simplifying the Measurement of Inventory. The new standard changed the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. The Company adopted this standard during the first quarter of 2017, and the adoption did not have an impact on the consolidated results of operations, cash flows or financial position of the Company. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The Company adopted ASU 2016-09 effective January 1, 2017, and the adoption did not have a significant impact on the Company’s consolidated financial statements. As required under previous GAAP, the Company had estimated forfeitures in determining its periodic compensation costs related to share-based awards. Upon adoption of the new standard, the Company has elected to recognize forfeitures as they occur, and recorded a cumulative effect adjustment to accumulated deficit and additional paid-in capital of $97,000, the net of which had no impact on the Company’s consolidated results of operations, cash flows or financial position. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). This new standard eliminates Step 2 from the goodwill impairment test. ASU 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. ASU 2017-04 still allows the option to perform a qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The Company early adopted this standard effective January 1, 2017 and will apply the standard prospectively for its annual goodwill impairment tests.  The adoption of the standard did not have an impact on the Company’s consolidated financial statements. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements Not Yet Adopted <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), supplemented with a number of subsequent amendments issued by the FASB and collectively referred to herein as “ASU 2014-09”.  This guidance requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  The standard creates a five-step model that requires a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied.  This guidance also requires an entity to disclose sufficient information to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.  Qualitative and quantitative information is required about contract balances and remaining performance obligations, significant judgments made in determining the timing of satisfaction of performance obligations (over time or at a point in time), and estimates made in determining the transaction price and amounts allocated to performance obligations. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to monitor and evaluate the impact the adoption of this standard will have on its consolidated financial statements and has performed an initial review of its major contracts with customers. Based on the initial reviews, the Company believes the adoption of the new standard may accelerate the timing of revenue recognition for certain product sales and development revenue under certain license, development and supply agreements, and will require management to estimate and potentially recognize certain variable revenue streams such as royalties and profit sharing arrangements earlier at an amount it believes will not be subject to significant reversal. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company anticipates adopting the new revenue recognition standard on the effective date of January 1, 2018 utilizing the modified retrospective method of adoption, under which the cumulative effect of the change is recognized as an adjustment to the opening balance of the accumulated deficit within the consolidated balance sheet, and prior reporting periods are not retrospectively adjusted. The Company anticipates recognizing a transition adjustment upon adoption, however the amount cannot currently be quantified, as the calculation of such will depend upon the open contracts and performance obligations as of the transition date. No significant changes to business processes or systems are currently expected to be necessary, as the processes and controls used in recording revenue transactions are largely manual. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). This new standard requires entities to recognize on its balance sheet assets and liabilities associated with the rights and obligations created by leases with terms greater than twelve months. This new standard is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those annual periods and early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements and currently expects that most of its operating lease commitments will be subject to the new standard and recognized as operating lease liabilities and right-of-use assets in the statement of financial position upon adoption of ASU 2016-02. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”), which provides guidance on determining which changes to terms and conditions of share-based awards require an entity to apply modification accounting under Topic 718. This new standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods, and early adoption is permitted. The adoption of ASU 2017-09 is not expected to have a significant impact on the Company’s consolidated financial statements. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No. 2017-05, Other Income – Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”).  The amendments clarify that an entity should identify each distinct nonfinancial asset or in-substance nonfinancial asset promised to a counterparty and derecognize each asset when a counterparty obtains control of it. ASU 2017-05 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within those annual periods.  The Company is currently evaluating the potential impact, if any, on its consolidated financial statements upon the adoption of ASU 2017-05 and expects to adopt the standard effective January 1, 2018.  </div>

<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2017:      <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,313,909</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.84</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,975,667</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.67</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,062,693</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.57</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(833,033</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.68</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,393,850</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,631,780</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,043,282</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.93</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.4%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,880,581</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annualized volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.4%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.6%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average expected life, in years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the TSR PSUs granted was determined using a Monte Carlo simulation and utilized the following inputs and assumptions:  <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017 Award</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016 Award</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015 Award</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Closing stock price on grant date</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.66</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.18</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance period starting price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term of award (in years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.59</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.97</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.83</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value per TSR PSU</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Teva</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,663,701</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,522,996</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,043,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,513,972</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMAG</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767,702</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,369,950</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,338,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,275,832</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McKesson</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,339,238</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946,261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,333,080</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501,810</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AmerisourceBergen</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,470,268</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,156,566</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,323,013</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,658,453</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ferring</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723,502</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246,300</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,018,098</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,960,689</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

1000000

900000

126070

142491

4357554

2429075

3458752

2755396

1297054

254425 -1042629 0.01

650000

1986553

1540488

0.02 0.50

35000000

25000000

Under the terms of the Loan Agreement, the Company may, but is not obligated to, request one or more additional advances of at least $5,000,000 not to exceed $10,000,000 in the aggregate, subject to the Company achieving certain corporate milestones and satisfying customary conditions.

5000000

10000000

The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022

2022-07-01

0.0950

0.0875

Payments under the Loan Agreement are interest only until the first principal payment is due on August 1, 2019, provided that the interest only period may be extended to February 1, 2020 if the Company achieves certain corporate milestones.

2019-08-01

2020-02-01 0.0425 0.010 0.030

24791214

25000000

66406

275192

3075781

7870277

8602959

6513483

26062500

30000000

0.030

32200000

4000000

1.00

P10Y

P3Y

P1Y

6400000

11313909

2975667

1062693

833033

12393850

8043282

1.84

2.67

1.57

2.68

2.01

1.93

P7Y3M18D

P6Y2M12D

15631780

10880581

1.62

0.54

0.018

0.013

0.534

0.516

P6Y

0.000

1670149

24071

1062693

21492

1680437

1572710

692834

505663

4500000

P2Y1M6D

P10Y

P3Y

P5Y

1347289

822658

689180

287508

502308

67464

1534161

1156866

1.50

1.39

3.12

2.69

1.49

2.16

1.70

2.20

2.12

0.00 1.50 2.66 1.12 2.18 2.17 1.29 2.52

P2Y6M25D

P2Y6M29D

P2Y7M2D

0.546

0.701

0.605

0.0139

0.0097

0.0083

0.0000

3.10 1.25 1.71

239995

11331

451021

302782

97586

65575

14174112

12036590

37009301

33631332

750470

1215218

3018099

3829809

127815

226955

448615

564784

7663701

5522996

17043954

18513972

1767702

2369950

6338275

3275832

2339238

1946261

6333080

5501810

1470268

1156566

4323013

3658453

723502

1246300

3018098

3960689

15084877

14100835

97000 14500000 4 The purchase price is to be paid in four installments consisting of the following: a $2.0 million upfront payment received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million payable upon delivery of certain documentation and satisfaction of certain conditions primarily related to Product manufacturing; a third installment of $4.75 million payable upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million upon Ferring’s receipt of the CE Mark needed to continue to commercialize the Product in certain territories and the final transfer of certain Product-related inventory, equipment and agreements to Ferring (the “Completion Date”), which is expected to occur by the end of 2018. 2000000 2750000 4750000 5000000

EX-101.SCH 7 atrs-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Basis of Presentation and Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Share Based Compensation link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Significant Customers and Concentrations of Risk link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Share Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Significant Customers and Concentrations of Risk (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Basis of Presentation and Significant Accounting Policies - Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Long-Term Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Including End of Term Charge (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Share Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Share Based Compensation - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Share Based Compensation - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Significant Customers and Concentrations of Risk - Summary of Revenues by Customer Location (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Net Loss Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 atrs-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 atrs-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 atrs-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current Assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Accounts receivable Accounts Receivable Net Current Inventories Inventory Net Deferred costs Deferred Costs Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Equipment, molds, furniture and fixtures, net Property Plant And Equipment Net Patent rights, net Finite Lived Intangible Assets Net Goodwill Goodwill Other assets Other Assets Noncurrent Total Assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current Liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses and other liabilities Accrued Liabilities Current Deferred revenue Deferred Revenue Current Total current liabilities Liabilities Current Long-term debt Long Term Debt Noncurrent Deferred revenue – long term Deferred Revenue Noncurrent Total liabilities Liabilities Stockholders’ Equity: Stockholders Equity [Abstract] Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding Preferred Stock Value Outstanding Common Stock: $0.01 par; 300,000,000 shares authorized; 156,425,904 and 155,167,677 issued and outstanding at September 30, 2017 and December 31, 2016, respectively Common Stock Value Outstanding Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Total Stockholders' Equity Stockholders Equity Total Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity Preferred Stock, par value Preferred Stock Par Or Stated Value Per Share Preferred Stock, shares authorized Preferred Stock Shares Authorized Preferred Stock, shares outstanding Preferred Stock Shares Outstanding Common Stock, par value Common Stock Par Or Stated Value Per Share Common Stock, shares authorized Common Stock Shares Authorized Common Stock, shares issued Common Stock Shares Issued Common Stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenue: Revenues [Abstract] Product sales Sales Revenue Goods Net Development revenue Contracts Revenue Licensing revenue Licenses Revenue Royalties Royalty Revenue Total revenue Revenues Cost of revenue: Cost Of Revenue [Abstract] Cost of product sales Cost Of Goods Sold Cost of development revenue Contract Revenue Cost Total cost of revenue Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income Loss Interest expense Interest Expense Other income Other Nonoperating Income Expense Net loss Net Income Loss Basic and diluted net loss per common share Earnings Per Share Basic And Diluted Basic and diluted weighted average common shares outstanding Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Foreign currency translation adjustment Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent Comprehensive loss Comprehensive Income Net Of Tax Future cash outflow to pay for purchases of intangible assets that have occurred. Operating Cash Flows Direct Method [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation expense Share Based Compensation Depreciation and amortization Depreciation Depletion And Amortization Loss on disposal of equipment Gain Loss On Sale Of Property Plant Equipment Write-off of capitalized patent costs Amortization Of Intangible Assets Accretion of interest expense Accretion Expense Amortization of debt issuance costs Amortization Of Financing Costs Amortization of premiums and discounts on investment securities Accretion Amortization Of Discounts And Premiums Investments Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Deferred costs Increase Decrease In Deferred Charges Accounts payable Increase Decrease In Accounts Payable Accrued expenses and other current liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Deferred revenue Increase Decrease In Deferred Revenue Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchase of investment securities Payments To Acquire Investments Purchases of equipment, molds, furniture and fixtures Payments To Acquire Property Plant And Equipment Additions to patent rights Payments To Acquire Intangible Assets Proceeds from maturities of investment securities Proceeds From Sale Maturity And Collection Of Shortterm Investments Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of long-term debt Proceeds From Issuance Of Long Term Debt Payment of debt issuance costs Payments Of Debt Issuance Costs Proceeds from exercise of stock options Proceeds From Stock Options Exercised Taxes paid related to net share settlement of equity awards Payments Related To Tax Withholding For Share Based Compensation Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Effect of exchange rate changes on cash Effect Of Exchange Rate On Cash Net decrease in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents: Cash And Cash Equivalents At Carrying Value [Abstract] Beginning of period End of period Supplemental disclosure of non-cash investing activities: Noncash Investing And Financing Items [Abstract] Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses Capital Expenditures Incurred But Not Yet Paid Additions to patent rights recorded in accounts payable and accrued expenses Additions To Patent Rights Recorded In Accounts Payable And Accrued Expenses Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Nature Of Operations Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Debt Disclosure [Abstract] Long-Term Debt Long Term Debt [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Risks And Uncertainties [Abstract] Significant Customers and Concentrations of Risk Concentration Risk Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] New Accounting Pronouncements And Changes In Accounting Principles [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Investments Investment Policy [Text Block] Inventories Inventory Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Inventories Schedule Of Inventory Current Table [Text Block] Schedule of Future Principal Payments under Term Loan, Including End of Term Charge Schedule Of Maturities Of Long Term Debt Table [Text Block] Statement [Table] Statement [Table] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Performance Stock Units [Member] Performance Shares [Member] Statement [Line Items] Statement [Line Items] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Assumptions Used in Fair Value Measurement of Options Granted Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Tabular disclosure of share based compensation award performance based units and restricted stock units granted. Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program Schedule Of Share Based Compensation Award Performance Based Units And Restricted Stock Units Granted Table [Text Block] Summary of Revenues by Customer Location Revenue From External Customers By Geographic Areas Table [Text Block] Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block] Regulatory assets. Regulatory Assets [Abstract] Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Products and Services Product Or Service [Axis] Products and Services Products And Services [Domain] OTREXUP. OTREXUP [Member] Otrexup [Member] Range Range [Axis] Range Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Teva. Teva [Member] Teva [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Carrying value of investments Inventory reserve Inventory Valuation Reserves Inventory Disclosure [Abstract] Inventories: Increase Decrease In Inventories [Abstract] Raw material Inventory Raw Materials Net Of Reserves Work in process Inventory Work In Process Net Of Reserves Finished goods Inventory Finished Goods Net Of Reserves Inventory, Total Revenue recognition, changes in net income (loss). Revenue recognition, changes in earnings per share. Deferred costs cost recognized. Additional revenue recognized, not previously recognized Deferred Revenue Revenue Recognized1 Related product costs recognized Deferred Costs Cost Recognized Revenue Recognition, decrease in net loss Revenue Recognition Changes In Net Income Loss Revenue Recognition, decrease in net loss per share Revenue Recognition Changes In Earnings Per Share Estimated product returns reserve Revenue Recognition Sales Returns Reserve For Sales Returns Product sales allowances Sales Allowances Goods The discount % offered to customers for prompt payment. Cash discount to incentive for prompt payment Cash Discount Percent Future net profits from commercial sales percent. Future net profits from commercial sales percent Future Net Profits From Commercial Sales Percent Debt Instrument [Table] Debt Instrument [Table] Lender Name Line Of Credit Facility [Axis] Line of Credit Facility, Lender Line Of Credit Facility Lender [Domain] Hercules Capital, Inc., Hercules Capital, Inc [Member] Hercules Capital Inc [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Term loan. Term Loan [Member] Term Loan [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] Prime Based Variable Rate [Member] Prime Rate [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long-tem debt, face amount Debt Instrument Face Amount Advance of funded upon execution of loan agreement Debt Instrument, covenant description Debt Instrument Covenant Description Amount of additional advances Company may request Debt Instrument Unused Borrowing Capacity Amount Percentage of loan fee on original principal amount. Prepayment fee percentage on principal loan prepaid Debt instrument extented date of first required amount. EX-101.PRE 11 atrs-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 01, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	ATRS
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	0001016169
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		156,674,504

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 27,433,489	$ 27,714,588
Short-term investments	9,976,984	0
Accounts receivable	10,146,966	9,073,173
Inventories	7,942,376	5,326,962
Deferred costs	1,213,507	1,773,446
Prepaid expenses and other current assets	1,680,208	1,376,299
Total current assets	58,393,530	45,264,468
Equipment, molds, furniture and fixtures, net	17,296,719	17,867,412
Patent rights, net	1,630,785	2,044,608
Goodwill	1,095,355	1,095,355
Other assets	53,778	53,607
Total Assets	78,470,167	66,325,450
Current Liabilities:
Accounts payable	8,245,154	7,884,983
Accrued expenses and other liabilities	6,394,379	5,872,846
Deferred revenue	2,842,801	6,149,087
Total current liabilities	17,482,334	19,906,916
Long-term debt	24,791,214
Deferred revenue – long term	200,000	1,200,000
Total liabilities	42,473,548	21,106,916
Stockholders’ Equity:
Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding
Common Stock: $0.01 par; 300,000,000 shares authorized; 156,425,904 and 155,167,677 issued and outstanding at September 30, 2017 and December 31, 2016, respectively	1,564,259	1,551,677
Additional paid-in capital	301,703,929	297,826,433
Accumulated deficit	(266,570,874)	(253,445,306)
Accumulated other comprehensive loss	(700,695)	(714,270)
Total Stockholders' Equity	35,996,619	45,218,534
Total Liabilities and Stockholders’ Equity	$ 78,470,167	$ 66,325,450

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	156,425,904	155,167,677
Common Stock, shares outstanding	156,425,904	155,167,677

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Product sales	$ 13,327,525	$ 11,049,840	$ 30,708,750	$ 30,580,889
Development revenue	1,485,091	2,101,203	7,894,640	6,466,974
Licensing revenue	19,486	38,618	1,057,204	128,040
Royalties	220,295	289,102	815,421	850,022
Total revenue	15,052,397	13,478,763	40,476,015	38,025,925
Cost of revenue:
Cost of product sales	7,600,180	7,206,280	16,681,689	18,670,363
Cost of development revenue	922,717	827,441	3,677,363	3,457,197
Total cost of revenue	8,522,897	8,033,721	20,359,052	22,127,560
Gross profit	6,529,500	5,445,042	20,116,963	15,898,365
Operating expenses:
Research and development	3,289,445	5,958,550	9,535,089	15,554,599
Selling, general and administrative	8,185,865	5,622,937	23,013,130	20,240,635
Total operating expenses	11,475,310	11,581,487	32,548,219	35,795,234
Operating loss	(4,945,810)	(6,136,445)	(12,431,256)	(19,896,869)
Interest expense	(625,938)		(794,129)
Other income	119,227	15,462	197,003	58,313
Net loss	$ (5,452,521)	$ (6,120,983)	$ (13,028,382)	$ (19,838,556)
Basic and diluted net loss per common share	$ (0.03)	$ (0.04)	$ (0.08)	$ (0.13)
Basic and diluted weighted average common shares outstanding	156,400,702	155,060,811	155,851,639	154,952,060

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,452,521)	$ (6,120,983)	$ (13,028,382)	$ (19,838,556)
Foreign currency translation adjustment	(3,621)	2,632	13,575	(7,820)
Comprehensive loss	$ (5,456,142)	$ (6,118,351)	$ (13,014,807)	$ (19,846,376)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (13,028,382)	$ (19,838,556)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,371,453	1,886,823
Depreciation and amortization	1,520,197	1,371,538
Loss on disposal of equipment	22,600	17,785
Write-off of capitalized patent costs	45,600
Accretion of interest expense	66,406
Amortization of debt issuance costs	18,347
Amortization of premiums and discounts on investment securities	(16,638)	10,913
Changes in operating assets and liabilities:
Accounts receivable	(1,069,614)	(624,232)
Inventories	(2,615,414)	(999,158)
Prepaid expenses and other assets	(299,825)	2,922,527
Deferred costs	559,939	(762,413)
Accounts payable	701,704	3,308,607
Accrued expenses and other current liabilities	549,929	(146,376)
Deferred revenue	(4,308,571)	1,156,309
Net cash used in operating activities	(15,482,269)	(11,696,233)
Cash flows from investing activities:
Purchase of investment securities	(9,963,978)
Purchases of equipment, molds, furniture and fixtures	(878,855)	(4,278,643)
Additions to patent rights	(83,592)	(103,788)
Proceeds from maturities of investment securities		12,000,000
Net cash (used in) provided by investing activities	(10,926,425)	7,617,569
Cash flows from financing activities:
Proceeds from issuance of long-term debt	25,000,000
Payment of debt issuance costs	(293,538)
Proceeds from exercise of stock options	1,670,149	24,071
Taxes paid related to net share settlement of equity awards	(248,709)	(64,096)
Net cash provided by (used in) financing activities	26,127,902	(40,025)
Effect of exchange rate changes on cash	(307)	1,440
Net decrease in cash and cash equivalents	(281,099)	(4,117,249)
Cash and cash equivalents:
Beginning of period	27,714,588	32,898,676
End of period	27,433,489	28,781,427
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	92,674	552,556
Additions to patent rights recorded in accounts payable and accrued expenses	$ 6,160	$ 23,369

XML 18 R7.htm IDEA: XBRL DOCUMENT

Description of Business

9 Months Ended

Sep. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

1.	Description of Business

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

2.	Basis of Presentation and Significant Accounting Policies

Investments

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,000,000 and $900,000 at September 30, 2017 and December 31, 2016, respectively. Inventories consist of the following:

	September 30,		December 31,
	2017		2016
Inventories:
Raw material	$	126,070	$	142,491
Work in process		4,357,554		2,429,075
Finished goods		3,458,752		2,755,396
	$	7,942,376	$	5,326,962

Revenue Recognition — OTREXUP^®

Product Sales Allowances

Chargebacks. The Company provides discounts to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized.

Revenue Recognition — Sumatriptan Injection

XML 20 R9.htm IDEA: XBRL DOCUMENT

Long-Term Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Long-Term Debt

3.	Long-Term Debt

Future principal payments under the term loan, including the End of Term Charge, are as follows:

	September 30,
	2017
2017	$	—
2018		—
2019		3,075,781
2020		7,870,277
2021		8,602,959
Thereafter		6,513,483
	$	26,062,500

The Company believes that the carrying value of the Term Loan approximates its fair value based on the borrowing rates currently available for loans with similar terms.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Stockholders' Equity

4.	Stockholders’ Equity

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Share Based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share Based Compensation

5.	Share-Based Compensation

Stock Options

The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2017:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Shares			Price		Term (Years)		Value
Outstanding at December 31, 2016		11,313,909		$	1.84
Granted		2,975,667			2.67
Exercised		(1,062,693	)		1.57
Cancelled/Forfeited		(833,033	)		2.68
Outstanding at September 30, 2017		12,393,850			2.01		7.3	$	15,631,780
Exercisable at September 30, 2017		8,043,282		$	1.93		6.2	$	10,880,581

	September 30,
	2017		2016
Risk-free interest rate		1.8%		1.3%
Annualized volatility		53.4%		51.6%
Weighted average expected life, in years		6.0		6.0
Expected dividend yield		0.0%		0.0%

Long Term Incentive Program

The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table:

	Performance Stock Units					Restricted Stock Units
	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2016		1,347,289		$	1.50		822,658		$	1.39
Granted		689,180			3.12		689,180			2.69
Vested/settled		—					(287,508	)		1.49
Forfeited/expired		(502,308	)		2.16		(67,464	)		1.70
Outstanding at September 30, 2017		1,534,161		$	2.20		1,156,866		$	2.12

	2017 Award			2016 Award			2015 Award
Closing stock price on grant date	$	2.66		$	1.12		$	2.18
Performance period starting price	$	2.17		$	1.29		$	2.52
Term of award (in years)		2.57			2.58			2.59
Volatility		54.6	%		70.1	%		60.5	%
Risk-free interest rate		1.39	%		0.97	%		0.83	%
Expected dividend yield		0.00	%		0.00	%		0.00	%
Fair value per TSR PSU	$	3.10		$	1.25		$	1.71

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Significant Customers and Concentrations of Risk

9 Months Ended

Sep. 30, 2017

Risks And Uncertainties [Abstract]

Significant Customers and Concentrations of Risk

6.	Significant Customers and Concentrations of Risk

Revenues by customer location are summarized as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
United States of America	$	14,174,112	$	12,036,590	$	37,009,301	$	33,631,332
Europe		750,470		1,215,218		3,018,099		3,829,809
Other		127,815		226,955		448,615		564,784
	$	15,052,397	$	13,478,763	$	40,476,015	$	38,025,925

Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Teva	$	7,663,701	$	5,522,996	$	17,043,954	$	18,513,972
AMAG		1,767,702		2,369,950		6,338,275		3,275,832
McKesson		2,339,238		1,946,261		6,333,080		5,501,810
AmerisourceBergen		1,470,268		1,156,566		4,323,013		3,658,453
Ferring		723,502		1,246,300		3,018,098		3,960,689

XML 24 R13.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss Per Share

7.	Net Loss Per Share

XML 25 R14.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2017

New Accounting Pronouncements And Changes In Accounting Principles [Abstract]

Recent Accounting Pronouncements

8.	Recent Accounting Pronouncements

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

The Company anticipates adopting the new revenue recognition standard on the effective date of January 1, 2018 utilizing the modified retrospective method of adoption, under which the cumulative effect of the change is recognized as an adjustment to the opening balance of the accumulated deficit within the consolidated balance sheet, and prior reporting periods are not retrospectively adjusted. The Company anticipates recognizing a transition adjustment upon adoption, however the amount cannot currently be quantified, as the calculation of such will depend upon the open contracts and performance obligations as of the transition date. No significant changes to business processes or systems are currently expected to be necessary, as the processes and controls used in recording revenue transactions are largely manual.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

9.	Subsequent Events

ZOMAJET™ Asset Purchase Agreement

Litigation

XML 27 R16.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Investments

Inventories

	September 30,		December 31,
	2017		2016
Inventories:
Raw material	$	126,070	$	142,491
Work in process		4,357,554		2,429,075
Finished goods		3,458,752		2,755,396
	$	7,942,376	$	5,326,962

Revenue Recognition

Revenue Recognition — OTREXUP^®

Product Sales Allowances

Revenue Recognition — Sumatriptan Injection

Recent Accounting Pronouncements

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Inventories

Inventories consist of the following:

	September 30,		December 31,
	2017		2016
Inventories:
Raw material	$	126,070	$	142,491
Work in process		4,357,554		2,429,075
Finished goods		3,458,752		2,755,396
	$	7,942,376	$	5,326,962

XML 29 R18.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Future Principal Payments under Term Loan, Including End of Term Charge

Future principal payments under the term loan, including the End of Term Charge, are as follows:

	September 30,
	2017
2017	$	—
2018		—
2019		3,075,781
2020		7,870,277
2021		8,602,959
Thereafter		6,513,483
	$	26,062,500

XML 30 R19.htm IDEA: XBRL DOCUMENT

Share Based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Summary of Stock Option Activity

The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2017:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Shares			Price		Term (Years)		Value
Outstanding at December 31, 2016		11,313,909		$	1.84
Granted		2,975,667			2.67
Exercised		(1,062,693	)		1.57
Cancelled/Forfeited		(833,033	)		2.68
Outstanding at September 30, 2017		12,393,850			2.01		7.3	$	15,631,780
Exercisable at September 30, 2017		8,043,282		$	1.93		6.2	$	10,880,581

Assumptions Used in Fair Value Measurement of Options Granted

	September 30,
	2017		2016
Risk-free interest rate		1.8%		1.3%
Annualized volatility		53.4%		51.6%
Weighted average expected life, in years		6.0		6.0
Expected dividend yield		0.0%		0.0%

Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program

The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table:

	Performance Stock Units					Restricted Stock Units
	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2016		1,347,289		$	1.50		822,658		$	1.39
Granted		689,180			3.12		689,180			2.69
Vested/settled		—					(287,508	)		1.49
Forfeited/expired		(502,308	)		2.16		(67,464	)		1.70
Outstanding at September 30, 2017		1,534,161		$	2.20		1,156,866		$	2.12

Performance Stock Units [Member]

Assumptions Used in Fair Value Measurement of Options Granted

The fair values of the TSR PSUs granted was determined using a Monte Carlo simulation and utilized the following inputs and assumptions:

	2017 Award			2016 Award			2015 Award
Closing stock price on grant date	$	2.66		$	1.12		$	2.18
Performance period starting price	$	2.17		$	1.29		$	2.52
Term of award (in years)		2.57			2.58			2.59
Volatility		54.6	%		70.1	%		60.5	%
Risk-free interest rate		1.39	%		0.97	%		0.83	%
Expected dividend yield		0.00	%		0.00	%		0.00	%
Fair value per TSR PSU	$	3.10		$	1.25		$	1.71

XML 31 R20.htm IDEA: XBRL DOCUMENT

Significant Customers and Concentrations of Risk (Tables)

9 Months Ended

Sep. 30, 2017

Risks And Uncertainties [Abstract]

Summary of Revenues by Customer Location

Revenues by customer location are summarized as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
United States of America	$	14,174,112	$	12,036,590	$	37,009,301	$	33,631,332
Europe		750,470		1,215,218		3,018,099		3,829,809
Other		127,815		226,955		448,615		564,784
	$	15,052,397	$	13,478,763	$	40,476,015	$	38,025,925

Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue

Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Teva	$	7,663,701	$	5,522,996	$	17,043,954	$	18,513,972
AMAG		1,767,702		2,369,950		6,338,275		3,275,832
McKesson		2,339,238		1,946,261		6,333,080		5,501,810
AmerisourceBergen		1,470,268		1,156,566		4,323,013		3,658,453
Ferring		723,502		1,246,300		3,018,098		3,960,689

XML 32 R21.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)		3 Months Ended	9 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Carrying value of investments	$ 0		$ 9,976,984
Inventory reserve	900,000		$ 1,000,000
Cash discount to incentive for prompt payment				2.00%
Teva [Member]
Summary Of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent			50.00%
OTREXUP [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional revenue recognized, not previously recognized		$ 1,297,054
Related product costs recognized		$ 254,425
Revenue Recognition, decrease in net loss			$ 1,042,629
Estimated product returns reserve	0		650,000
Product sales allowances	$ 1,540,488		$ 1,986,553
OTREXUP [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition, decrease in net loss per share			$ 0.01

XML 33 R22.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Inventories (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Inventories:
Raw material	$ 126,070	$ 142,491
Work in process	4,357,554	2,429,075
Finished goods	3,458,752	2,755,396
Inventory, Total	$ 7,942,376	$ 5,326,962

XML 34 R23.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Additional Information (Detail) - USD ($)		9 Months Ended
	Jun. 06, 2017	Sep. 30, 2017
Debt Instrument [Line Items]
Advance of funded upon execution of loan agreement		$ 25,000,000
Carrying value of long term debt		$ 24,791,214
Hercules Capital, Inc [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Long-tem debt, face amount	$ 35,000,000
Advance of funded upon execution of loan agreement	$ 25,000,000
Debt Instrument, covenant description		Under the terms of the Loan Agreement, the Company may, but is not obligated to, request one or more additional advances of at least $5,000,000 not to exceed $10,000,000 in the aggregate, subject to the Company achieving certain corporate milestones and satisfying customary conditions.
Debt instrument, maturity date Description		The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022
Debt instrument, maturity date	Jul. 01, 2022
Debt Instrument, interest rate		8.75%
Debt instrument, payment terms		Payments under the Loan Agreement are interest only until the first principal payment is due on August 1, 2019, provided that the interest only period may be extended to February 1, 2020 if the Company achieves certain corporate milestones.
Debt instrument, first pricipal payment due date		Aug. 01, 2019
Debt instrument, first pricipal payment may be extended date		Feb. 01, 2020
Percentage of loan fee on original principal amount		4.25%
Carrying value of long term debt		$ 24,791,214
Principal balance outstanding		25,000,000
Term charge accrual		66,406
Unamortized debt issuance costs		$ 275,192
Hercules Capital, Inc [Member] \| Term Loan [Member] \| Prime Based Variable Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, variable interest rate	9.50%
Hercules Capital, Inc [Member] \| Term Loan [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid		1.00%
Hercules Capital, Inc [Member] \| Term Loan [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid		3.00%
Hercules Capital, Inc [Member] \| Term Loan [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Amount of additional advances Company may request	$ 5,000,000
Hercules Capital, Inc [Member] \| Term Loan [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Amount of additional advances Company may request	$ 10,000,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Including End of Term Charge (Detail)	Sep. 30, 2017 USD ($)
Debt Disclosure [Abstract]
2019	$ 3,075,781
2020	7,870,277
2021	8,602,959
Thereafter	6,513,483
Long-term debt	$ 26,062,500

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - Sales Agreement [Member] - Cowen and Company, LLC [Member]	Aug. 11, 2017 USD ($)
Stockholders Equity [Line Items]
Percentage of commission on proceeds from gross sales of common stock	3.00%
Proceeds from sale of common stock	$ 0
Maximum [Member]
Stockholders Equity [Line Items]
Aggregate offering price of common stock	$ 30,000,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from the issuance of stock options			$ 1,670,149	$ 24,071
Shares withheld to meet employees' minimum statutory income tax obligation			97,586	65,575
Payments for the employees' minimum statutory income tax obligation			$ 248,709	$ 64,096
Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized	32,200,000		32,200,000
Maximum number of shares of stock granted to one participant			4,000,000
Minimum percentage of exercise price			100.00%
Shares available for grant under the plan	6,400,000		6,400,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Per share weighted average fair values of options granted			$ 1.62	$ 0.54
Proceeds from the issuance of stock options			$ 1,670,149	$ 24,071
Exercise of options, shares			1,062,693	21,492
Recognized compensation cost related to shares of stock granted	$ 692,834	$ 505,663	$ 1,680,437	$ 1,572,710
Unrecognized compensation cost related to nonvested outstanding stock awards	$ 4,500,000		$ 4,500,000
Weighted average period expected to be recognized			2 years 1 month 6 days
Stock Options [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted			10 years
Vesting period			3 years
Stock Options [Member] \| Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted			10 years
Vesting period			3 years
Stock Options [Member] \| Minimum [Member] \| Amended and Restated 2008 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Restricted Stock Units [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Recognized compensation cost related to shares of stock granted			$ 451,021	302,782
Performance Stock Units [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized compensation cost related to shares of stock granted			$ 239,995	$ 11,331
Performance Stock Units [Member] \| Minimum [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Share based compensation award percentage			0.00%
Performance Stock Units [Member] \| Maximum [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			5 years
Share based compensation award percentage			150.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Stock Option Activity (Detail)	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Stockholders Equity Note [Abstract]
Number of Shares Outstanding, Beginning Balance \| shares	11,313,909
Number of Shares Granted \| shares	2,975,667
Number of Shares Exercised \| shares	(1,062,693)
Number of Shares Cancelled/Forfeited \| shares	(833,033)
Number of Shares Outstanding, Ending Balance \| shares	12,393,850
Number of Shares Exercisable, Ending Balance \| shares	8,043,282
Weighted Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 1.84
Weighted Average Exercise Price Granted \| $ / shares	2.67
Weighted Average Exercise Price Exercised \| $ / shares	1.57
Weighted Average Exercise Price Cancelled/Forfeited \| $ / shares	2.68
Weighted Average Exercise Price Outstanding, Ending Balance \| $ / shares	2.01
Weighted Average Exercise Price Exercisable, Ending Balance \| $ / shares	$ 1.93
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	7 years 3 months 18 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	6 years 2 months 12 days
Aggregate Intrinsic Value Outstanding, Ending Balance \| $	$ 15,631,780
Aggregate Intrinsic Value Exercisable, Ending Balance \| $	$ 10,880,581

XML 39 R28.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Risk-free interest rate	1.80%	1.30%
Annualized volatility	53.40%	51.60%
Weighted average expected life, in years	6 years	6 years
Expected dividend yield	0.00%	0.00%

XML 40 R29.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail)	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance \| shares	1,347,289
Number of Shares, Granted \| shares	689,180
Number of Shares, Forfeited/expired \| shares	(502,308)
Number of Shares, Ending Balance \| shares	1,534,161
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 1.50
Weighted Average Grant Date Fair Value, Granted \| $ / shares	3.12
Weighted Average Grant Date Fair Value, Forfeited/expired \| $ / shares	2.16
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 2.20
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance \| shares	822,658
Number of Shares, Granted \| shares	689,180
Number of Shares, Vested/settled \| shares	(287,508)
Number of Shares, Forfeited/expired \| shares	(67,464)
Number of Shares, Ending Balance \| shares	1,156,866
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 1.39
Weighted Average Grant Date Fair Value, Granted \| $ / shares	2.69
Weighted Average Grant Date Fair Value, Vested/settled \| $ / shares	1.49
Weighted Average Grant Date Fair Value, Forfeited/expired \| $ / shares	1.70
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 2.12

XML 41 R30.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award (in years)	6 years	6 years
Volatility	53.40%	51.60%
Risk-free interest rate	1.80%	1.30%
Expected dividend yield	0.00%	0.00%
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price on grant date	$ 2.66	$ 1.12	$ 2.18
Performance period starting price	$ 2.17	$ 1.29	$ 2.52
Term of award (in years)	2 years 6 months 25 days	2 years 6 months 29 days	2 years 7 months 2 days
Volatility	54.60%	70.10%	60.50%
Risk-free interest rate	1.39%	0.97%	0.83%
Expected dividend yield	0.00%	0.00%	0.00%
Fair value per TSR PSU	$ 3.10	$ 1.25	$ 1.71

XML 42 R31.htm IDEA: XBRL DOCUMENT

Significant Customers and Concentrations of Risk - Summary of Revenues by Customer Location (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Concentration Risk [Line Items]
Total revenues	$ 15,052,397	$ 13,478,763	$ 40,476,015	$ 38,025,925
United States of America [Member]
Concentration Risk [Line Items]
Total revenues	14,174,112	12,036,590	37,009,301	33,631,332
Europe [Member]
Concentration Risk [Line Items]
Total revenues	750,470	1,215,218	3,018,099	3,829,809
Other [Member]
Concentration Risk [Line Items]
Total revenues	$ 127,815	$ 226,955	$ 448,615	$ 564,784

XML 43 R32.htm IDEA: XBRL DOCUMENT

Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Concentration Risk [Line Items]
Total revenues	$ 15,052,397	$ 13,478,763	$ 40,476,015	$ 38,025,925
Teva [Member]
Concentration Risk [Line Items]
Total revenues	7,663,701	5,522,996	17,043,954	18,513,972
AMAG [Member]
Concentration Risk [Line Items]
Total revenues	1,767,702	2,369,950	6,338,275	3,275,832
McKesson [Member]
Concentration Risk [Line Items]
Total revenues	2,339,238	1,946,261	6,333,080	5,501,810
AmerisourceBergen [Member]
Concentration Risk [Line Items]
Total revenues	1,470,268	1,156,566	4,323,013	3,658,453
Ferring [Member]
Concentration Risk [Line Items]
Total revenues	$ 723,502	$ 1,246,300	$ 3,018,098	$ 3,960,689

XML 44 R33.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Additional Information (Detail) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share	15,084,877	14,100,835

XML 45 R34.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017 USD ($)
ASU 2016-09 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Cumulative effect adjustment to accumulated deficit and additional paid-in capital	$ 97,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - Asset Purchase Agreement [Member] - Ferring [Member] - ZOMAJET [Member] - Subsequent Event [Member] $ in Thousands	Oct. 10, 2017 USD ($) Installment
Subsequent Event [Line Items]
Total purchase price	$ 14,500
Number of installments paid for purchase price \| Installment	4
Description of purchase price payment	The purchase price is to be paid in four installments consisting of the following: a $2.0 million upfront payment received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million payable upon delivery of certain documentation and satisfaction of certain conditions primarily related to Product manufacturing; a third installment of $4.75 million payable upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million upon Ferring’s receipt of the CE Mark needed to continue to commercialize the Product in certain territories and the final transfer of certain Product-related inventory, equipment and agreements to Ferring (the “Completion Date”), which is expected to occur by the end of 2018.
Upfront payment received upon transfer of assets	$ 2,000
Consideration receivable on criteria completion related to product manufacturing	2,750
Consideration receivable on criteria completion related to Audit and pilot manufacturing	4,750
Consideration receivable on criteria completion related to Product commercialization	$ 5,000

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 85 199 1 false 27 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.antarespharma.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.antarespharma.com/20170930/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.antarespharma.com/20170930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.antarespharma.com/20170930/taxonomy/role/StatementConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.antarespharma.com/20170930/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLossUnaudited Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.antarespharma.com/20170930/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Description of Business Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 7 false false R8.htm 100070 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Long-Term Debt Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureLongTermDebt Long-Term Debt Notes 9 false false R10.htm 100090 - Disclosure - Stockholders' Equity Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 10 false false R11.htm 100100 - Disclosure - Share Based Compensation Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensation Share Based Compensation Notes 11 false false R12.htm 100110 - Disclosure - Significant Customers and Concentrations of Risk Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSignificantCustomersAndConcentrationsOfRisk Significant Customers and Concentrations of Risk Notes 12 false false R13.htm 100120 - Disclosure - Net Loss Per Share Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 13 false false R14.htm 100130 - Disclosure - Recent Accounting Pronouncements Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 14 false false R15.htm 100140 - Disclosure - Subsequent Events Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 100150 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies 16 false false R17.htm 100160 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies 17 false false R18.htm 100170 - Disclosure - Long-Term Debt (Tables) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureLongTermDebtTables Long-Term Debt (Tables) Tables http://www.antarespharma.com/20170930/taxonomy/role/DisclosureLongTermDebt 18 false false R19.htm 100180 - Disclosure - Share Based Compensation (Tables) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensationTables Share Based Compensation (Tables) Tables http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensation 19 false false R20.htm 100190 - Disclosure - Significant Customers and Concentrations of Risk (Tables) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSignificantCustomersAndConcentrationsOfRiskTables Significant Customers and Concentrations of Risk (Tables) Tables http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSignificantCustomersAndConcentrationsOfRisk 20 false false R21.htm 100200 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 21 false false R22.htm 100210 - Disclosure - Basis of Presentation and Significant Accounting Policies - Inventories (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesInventoriesDetail Basis of Presentation and Significant Accounting Policies - Inventories (Detail) Details http://www.antarespharma.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables 22 false false R23.htm 100220 - Disclosure - Long-Term Debt - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail Long-Term Debt - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Including End of Term Charge (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureLongTermDebtScheduleOfFuturePrincipalPaymentsUnderTermLoanIncludingEndOfTermChargeDetail Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Including End of Term Charge (Detail) Details 24 false false R25.htm 100240 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 25 false false R26.htm 100250 - Disclosure - Share Based Compensation - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetail Share Based Compensation - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetail Share Based Compensation - Summary of Stock Option Activity (Detail) Details 27 false false R28.htm 100270 - Disclosure - Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInFairValueMeasurementOfOptionsGrantedDetail Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail) Details 28 false false R29.htm 100280 - Disclosure - Share Based Compensation - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensationScheduleOfPerformanceStockUnitAwardsAndRestrictedStockGrantedUnderLongTermIncentiveProgramDetail Share Based Compensation - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail) Details 29 false false R30.htm 100290 - Disclosure - Share Based Compensation - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureShareBasedCompensationFairValueOfPsusGrantedDeterminedUsingMonteCarloSimulationDetail Share Based Compensation - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) Details 30 false false R31.htm 100300 - Disclosure - Significant Customers and Concentrations of Risk - Summary of Revenues by Customer Location (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSignificantCustomersAndConcentrationsOfRiskSummaryOfRevenuesByCustomerLocationDetail Significant Customers and Concentrations of Risk - Summary of Revenues by Customer Location (Detail) Details 31 false false R32.htm 100310 - Disclosure - Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSignificantCustomersAndConcentrationsOfRiskSummaryOfSignificantCustomersFromWhichCompanyDerived10OrMoreOfTotalRevenueDetail Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) Details 32 false false R33.htm 100320 - Disclosure - Net Loss Per Share - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail Net Loss Per Share - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetail Recent Accounting Pronouncements - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.antarespharma.com/20170930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 35 false false All Reports Book All Reports atrs-20170930.xml atrs-20170930.xsd atrs-20170930_cal.xml atrs-20170930_def.xml atrs-20170930_lab.xml atrs-20170930_pre.xml http://fasb.org/us-gaap/2016-01-31 http://xbrl.sec.gov/country/2016-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 53 0001564590-17-022312-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-022312-xbrl.zip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�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